Myocardial Infarction

• 

  Subject Areas on Research

  • "Add-on" research in clinical trials: are we asking the right questions? 
  • "Hugging balloons" through a single 8-French guide: salvage angioplasty with lytic therapy in the infarct vessel of a 40-year-old man. 
  • "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction. 
  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • "Sticky" Issues for Adherence in Secondary Prevention. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 
  • 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 
  • 2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. 
  • 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice. 
  • 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. 
  • 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. 
  • 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 
  • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. 
  • 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. 
  • 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. 
  • 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. 
  • 23Na MRI combined with contrast-enhanced 1H MRI provides in vivo characterization of infarct healing. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A 69-year-old man with anger and angina. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A QRS scoring system for assessing left ventricular function after myocardial infarction. 
  • A bad day for quality control: sequential misplacement of left arm and left leg electrodes. 
  • A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. 
  • A clinical comparison of mitral valve repair versus valve replacement in ischemic mitral regurgitation. 
  • A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. 
  • A common variant on chromosome 9p21 affects the risk of myocardial infarction. 
  • A comparison of acute coronary syndrome care at academic and nonacademic hospitals. 
  • A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. 
  • A comparison of debulking versus dilatation of bifurcation coronary arterial narrowings (from the CAVEAT I Trial). Coronary Angioplasty Versus Excisional Atherectomy Trial-I. 
  • A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. 
  • A comparison of electrocardiographic QRS changes and two-dimensional echocardiographic left ventricular wall motion predischarge and in the 4th year following first acute myocardial infarction. 
  • A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A comparison of mortality, myocardial infarction, and repeated revascularization for sirolimus-eluting and paclitaxel-eluting coronary stents. 
  • A comparison of paramedic versus basic emergency medical care of patients at high and low risk during acute myocardial infarction. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). 
  • A comparison of three techniques for rapid model development: an application in patient risk-stratification. 
  • A detailed guide for quantification of myocardial scar with the Selvester QRS score in the presence of electrocardiogram confounders. 
  • A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. 
  • A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. 
  • A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. 
  • A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. 
  • A linear models application of competing risks to multiple causes of death. 
  • A magnetization-driven gradient echo pulse sequence for the study of myocardial perfusion. 
  • A man with chest pain and glomerulonephritis. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. 
  • A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. 
  • A method for assembling a collaborative research team from multiple disciplines and academic centers to study the relationships between ECG estimation and MRI measurement of myocardial infarct size. 
  • A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. 
  • A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. 
  • A new computer program for analysis of scalar electrocardiograms. 
  • A new computer program for comparative analysis of serial scalar electrocardiograms: description and performance of the 1976 IBM program. 
  • A new design for randomized trials. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A new look at an old therapy. 
  • A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging: a statement for healthcare professionals from a committee appointed by the International Society for Holter and Noninvasive Electrocardiography. 
  • A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A novel protective effect of erythropoietin in the infarcted heart. 
  • A novel, minimally invasive, segmental myocardial infarction with a clear healed infarct borderzone in rabbits. 
  • A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. 
  • A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. 
  • A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 
  • A previously unreported complication of apicoaortic conduit for severe aortic stenosis. 
  • A quality improvement framework for equity in cardiovascular care: results of a national collaborative. 
  • A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST) 
  • A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. 
  • A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 
  • A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. 
  • A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. 
  • A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction: the serial markers, acute myocardial infarction and rapid treatment trial (SMARTT). 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. 
  • A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale. 
  • A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. 
  • A sensitivity analysis of enzymatic estimation of infarct size. 
  • A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. 
  • A simplified method to predict occurrence of complete heart block during acute myocardial infarction. 
  • A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. 
  • A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. 
  • A theoretical analysis of acute ischemia and infarction using ECG reconstruction on a 2-D model of myocardium. 
  • A time-series analysis of the relation between unemployment rate and hospital admission for acute myocardial infarction and stroke in Brazil over more than a decade. 
  • ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). 
  • ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). 
  • ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). 
  • ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. 
  • ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. 
  • ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. 
  • ACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of performance measurement and reperfusion therapy). 
  • ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 
  • ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 
  • ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. 
  • ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 
  • ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). 
  • ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. 
  • ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. 
  • ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. 
  • ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. 
  • ACP Journal Club. Review: In patients having PCI, high-dose clopidogrel reduces major cardiac events vs standard-dose clopidogrel. 
  • ACP Journal Club. Review: in patients with heart failure, β-blockers reduce mortality but do not differ from each other. 
  • AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. 
  • AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. 
  • ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. 
  • ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Abi3bp regulates cardiac progenitor cell proliferation and differentiation. 
  • Abnormal cardiac enzyme responses after strenuous exercise: alternative diagnostic aids. 
  • Abnormal haemoglobin levels in acute coronary syndromes. 
  • Aborted infarction: the ultimate myocardial salvage. 
  • Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. 
  • Aborted myocardial infarction: a new target for reperfusion therapy. 
  • Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial. 
  • Absolute and relative truth in clinical trials. 
  • Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. 
  • Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. 
  • Accelerating ST-segment elevation myocardial infarction care: emergency medical services take center stage. 
  • Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. 
  • Accuracy of total serum enzymes and myocardial specific isoenzymes--a comparative study. 
  • Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. 
  • Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. 
  • Acquired dynamic left ventricular outflow tract obstruction complicating acute anterior myocardial infarction: serial echocardiographic and clinical evaluation. 
  • Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. 
  • Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute Coronary Syndrome Screening and Diagnostic Practice Variation. 
  • Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association. 
  • Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. 
  • Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Acute and long-term cost implications of coronary stenting. 
  • Acute circumferential subendocardial infarction. 
  • Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute coronary syndromes in patients with diabetes mellitus: diagnosis, prognosis, and current management strategies. 
  • Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. 
  • Acute coronary syndromes. STREAMlining care for patients with STEMI. 
  • Acute coronary syndromes: Blood transfusion in patients with acute MI and anaemia. 
  • Acute coronary syndromes: Right direction--moving proximally in timing of STEMI care. 
  • Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain. 
  • Acute coronary syndromes: introducing new therapies into established guidelines. 
  • Acute coronary syndromes: what have we learned about what we still need to know? 
  • Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. 
  • Acute ischemic heart disease. 
  • Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. 
  • Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. 
  • Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. 
  • Acute myocardial infarction in a young female. 
  • Acute myocardial infarction in a young male while playing paintball. 
  • Acute myocardial infarction in pregnancy: a United States population-based study. 
  • Acute myocardial infarction in sub-Saharan Africa: the need for data. 
  • Acute myocardial infarction with papillary muscle rupture. 
  • Acute myocardial infarction with ventricular septal rupture. 
  • Acute myocardial infarction. 
  • Acute myocardial infarction. Management after discharge from the coronary care unit. 
  • Acute myocardial infarction: profile and management at a tertiary care hospital in Karachi. 
  • Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. 
  • Acute results, complications, and effect of lesion characteristics on outcome with the solid-state, pulsed-wave, mid-infrared laser angioplasty system: final multicenter registry report. Holmium:YAG Laser Multicenter Investigators. 
  • Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. 
  • Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. 
  • Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. 
  • Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. 
  • Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. 
  • Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry. 
  • Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. 
  • Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. 
  • Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. 
  • Admission prediction of expected final myocardial infarct size using weighted ST-segment, Q wave, and T wave measurements. 
  • Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction. 
  • Adoption of thrombolytic therapy in the management of acute myocardial infarction. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Advancing biomarker science in the 21st century. 
  • Adverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study. 
  • Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. 
  • Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. 
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. 
  • Aerobic training enhances muscle deoxygenation in early post-myocardial infarction. 
  • After fibrinolysis: is cardiac catheterization the answer? 
  • After myocardial infarction. How to determine future risk and what to do then. 
  • Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. 
  • Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. 
  • Age and outcome after acute coronary syndromes without persistent ST-segment elevation. 
  • Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. 
  • Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial. 
  • Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. 
  • Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. 
  • Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. 
  • Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial. 
  • Aggressive therapy of acute MI in the elderly. 
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 
  • Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. 
  • Altered phosphate metabolism in myocardial infarction: P-31 MR spectroscopy. 
  • Alternative pay-for-performance scoring methods: implications for quality improvement and patient outcomes. 
  • Ameliorating reperfusion injury in STEMI: dead or alive? 
  • American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). 
  • American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • An Unexpected Finding in SUDEP Involving a Child: Focal Myocardial Infarct Adjacent to Bundle of His. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. 
  • An assessment of ST-segment measurement variability between two core electrocardiogram laboratories. 
  • An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. 
  • An economic analysis of an aggressive diagnostic strategy with single photon emission computed tomography myocardial perfusion imaging and early exercise stress testing in emergency department patients who present with chest pain but nondiagnostic electrocardiograms: results from a randomized trial. 
  • An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. 
  • An evaluation of factors influencing Bayesian learning systems. 
  • An improved MR imaging technique for the visualization of myocardial infarction. 
  • An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. 
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 
  • An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. 
  • An introduction to transoesophageal echocardiography: II. Clinical applications. 
  • An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. 
  • An overview of the results of the EPIC trial. 
  • An update on acute myocardial infarction from recent clinical trials. 
  • An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. 
  • Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. 
  • Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. 
  • Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. 
  • Analysis of risk factors for sudden death after acute myocardial infarction. 
  • Analysis of the components of CHD risk in the Framingham study: new multivariate procedures for the analysis of chronic disease development. 
  • Anatomic distribution of the culprit lesion in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: findings from the National Cardiovascular Data Registry. 
  • Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. 
  • Anatomic validation of electrocardiographic estimation of the size of acute or healed myocardial infarcts. 
  • Anatomical and functional imaging of myocardial infarction in mice using micro-CT and eXIA 160 contrast agent. 
  • Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. 
  • Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Angina frequency after myocardial infarction and quality of life in older versus younger adults: the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. 
  • Angiographic changes in vein grafts: stable surrogate or seductive siren? 
  • Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. 
  • Angiographic morphology in unstable angina pectoris. 
  • Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Emory Angioplasty versus Surgery Trial Investigators. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. 
  • Another biomarker for risk assessment in acute myocardial infarction? 
  • Answers to complex questions cannot be derived from "simple" trials. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. 
  • Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. 
  • Anticoagulation in heart failure: current status and future direction. 
  • Anticoagulation in transradial percutaneous coronary intervention. 
  • Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. 
  • Antidepressant use and the risk of myocardial infarction. 
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy beyond 2012: role of personalized medicine. 
  • Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 
  • Antithrombin alternatives in STEMI. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 
  • Anxiety, independent of depressive symptoms, is associated with in-hospital cardiac complications after acute myocardial infarction. 
  • Anxiety-proneness and coronary heart disease. 
  • Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit? 
  • Aortic counterpulsation: a review of the hemodynamic effects and indications for use. 
  • Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. 
  • Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. 
  • Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Appropriateness of percutaneous coronary intervention. 
  • Aprotinin: safe and effective only with the full-dose regimen. 
  • Arctigenin Attenuates Ischemia/Reperfusion Induced Ventricular Arrhythmias by Decreasing Oxidative Stress in Rats. 
  • Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. 
  • Are sleep complaints an independent risk factor for myocardial infarction? 
  • Arrhythmias in acute myocardial infarction. 
  • Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. 
  • Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. 
  • Arterial stiffness and cardiovascular events: the Framingham Heart Study. 
  • As originally published in 1989: Correlates of survival in patients with postinfarction ventricular septal defect. Updated in 1997. 
  • Aspergillus myocarditis presenting as myocardial infarction with complete heart block. 
  • Aspirin dose and six-month outcome after an acute coronary syndrome. 
  • Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. 
  • Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? 
  • Assessing oral beta-blocker therapy after percutaneous coronary intervention for ST-segment elevation myocardial infarction: the role of observational data. 
  • Assessing risk in FRISC. 
  • Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Assessing the clinical and economic burden of coronary artery disease: 1986-1998. 
  • Assessment of Administrative Data to Identify Acute Myocardial Infarction in Electronic Health Records. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. 
  • Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. 
  • Assessment of left ventricular function by resting and exercise radionuclide angiocardiography following acute myocardial infarction. 
  • Assessment of microvascular injury after acute myocardial infarction: importance of the area at risk. 
  • Assessment of myocardial infarction by cardiac magnetic resonance imaging and long-term mortality. 
  • Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study. 
  • Assessment of regional wall motion abnormalities with real-time 3-dimensional echocardiography. 
  • Assessment of temporal trends in mortality with implementation of a statewide ST-segment elevation myocardial infarction (STEMI) regionalization program. 
  • Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. 
  • Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. 
  • Association between ST segment Resolution following Fibrinolytic therapy or Intracoronary stenting, and Reinfarction in the same myocardial region in the DANAMI-2 study population. 
  • Association between angina and treatment satisfaction after myocardial infarction. 
  • Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. 
  • Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. 
  • Association between divorce and risks for acute myocardial infarction. 
  • Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. 
  • Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. 
  • Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Association between n-3 fatty acid consumption and ventricular ectopy after myocardial infarction. 
  • Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. 
  • Association between perceived life chaos and medication adherence in a postmyocardial infarction population. 
  • Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. 
  • Association between stroke center hospitalization for acute ischemic stroke and mortality. 
  • Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. 
  • Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. 
  • Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women. 
  • Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. 
  • Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry. 
  • Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. 
  • Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction. 
  • Association of bleeding and in-hospital mortality in black and white patients with st-segment-elevation myocardial infarction receiving reperfusion. 
  • Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. 
  • Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. 
  • Association of early follow-up after acute myocardial infarction with higher rates of medication use. 
  • Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients. 
  • Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. 
  • Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. 
  • Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. 
  • Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. 
  • Association of noninvasive markers of coronary artery reperfusion to assess microvascular obstruction in patients with acute myocardial infarction treated with primary angioplasty. 
  • Association of patient case-mix adjustment, hospital process performance rankings, and eligibility for financial incentives. 
  • Association of previous coronary artery bypass graft surgery with door-to-balloon time and in-hospital outcomes: a report from the National Cardiovascular Data Registry (NCDR). 
  • Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. 
  • Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. 
  • Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. 
  • Association of standard clinical and laboratory variables with red blood cell distribution width. 
  • Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. 
  • Association of the ankle-brachial index with history of myocardial infarction and stroke. 
  • Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. 
  • Associations Between Residential Proximity to Traffic and Vascular Disease in a Cardiac Catheterization Cohort. 
  • Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. 
  • At home thrombolysis. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. 
  • Atherosclerotic risk factors and their association with hospital mortality among patients with first myocardial infarction (from the National Registry of Myocardial Infarction). 
  • Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. 
  • Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. 
  • Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. 
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Augmentation of coronary collateral blood flow in acute myocardial infarction. 
  • Augmentation of mortality risk discriminating power of left ventricular ejection fraction by measures of nonuniformity in systolic emptying on radionuclide ventriculography. 
  • Automatic QRS Selvester scoring system in patients with left bundle branch block. 
  • Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 
  • B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. 
  • B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. 
  • Balancing the cyclooxygenase portfolio. 
  • Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. 
  • Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. 
  • Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 
  • Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry. 
  • Baseline bleeding risk and benefit of transradial PCI: making lemonade out of lemons. 
  • Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. 
  • Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Baseline glucose and left ventricular remodeling after acute myocardial infarction. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. 
  • Basic emergency medical care of patients with acute myocardial infarction: initial prehospital characteristics and in-hospital complications. 
  • Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. 
  • Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients? 
  • Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. 
  • Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. 
  • Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. 
  • Biochemical markers in suspected acute myocardial infarction: the need for early assessment. 
  • Biochemical markers of early reperfusion. 
  • Biomarker-based risk prediction in the community. 
  • Biomarkers in stable coronary artery disease. 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Biosensibility of viability: NOGA or no good? 
  • Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. 
  • Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. 
  • Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. 
  • Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Bleeding in acute coronary syndromes. 
  • Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. 
  • Blood-gas and hemodynamic responses to oxygen in acute myocardial infarction. 
  • Blunted cyclic variation of heart rate predicts mortality risk in post-myocardial infarction, end-stage renal disease, and chronic heart failure patients. 
  • Body mass index and effectiveness of reperfusion strategies: implications for the management of patients with ST-elevation myocardial infarction. 
  • Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Bradyarrhythmias in acute myocardial infarction. 
  • Branch retinal vein occlusion and optic nerve head topographic parameters: the Singapore Indian eye study. 
  • Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. 
  • Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. 
  • Bypassing the emergency department and time to reperfusion in patients with prehospital ST-segment-elevation: findings from the reperfusion in acute myocardial infarction in Carolina Emergency Departments project. 
  • C-reactive protein: a novel marker of cardiovascular risk. 
  • CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift? 
  • CORR Insights(®): Risk of Post-TKA Acute Myocardial Infarction in Patients With a History of Myocardial Infarction or Coronary Stent. 
  • CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. 
  • Calcium channel blockers and mortality in elderly patients with myocardial infarction. 
  • Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. 
  • Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. 
  • Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. 
  • Cardiac arrest complicating acute myocardial infarction: predictability and prognosis. 
  • Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: insights from the National Cardiovascular Data Registry. 
  • Cardiac imaging impaired by a silicone breast implant. 
  • Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. 
  • Cardiac marker testing: where should we focus? 
  • Cardiac markers following cardiac surgery and percutaneous coronary intervention. 
  • Cardiac markers for myocardial infarction. A brief review. 
  • Cardiac markers in the assessment of acute coronary syndromes. 
  • Cardiac markers: point of care testing. 
  • Cardiac output and associated cardiovascular responses to bed making. 
  • Cardiac potentials on body surface of infants with anomalous left coronary artery (myocardial infarction). 
  • Cardiac regenerative capacity and mechanisms. 
  • Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. 
  • Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. 
  • Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. 
  • Cardiac tissue engineering using stem cells. 
  • Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. 
  • Cardiac troponin T concentrations above the 99th percentile value as measured by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary syndromes undergoing routine early invasive strategy. 
  • Cardiac troponin release following hybrid coronary revascularization versus off-pump coronary artery bypass surgery. 
  • Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. 
  • Cardiogenic shock and awe. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. 
  • Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. 
  • Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction. 
  • Cardiology Patient Page. Depression after heart attack: why should I be concerned about depression after a heart attack? 
  • Cardiology patient page. Heart attack and stroke prevention in women. 
  • Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cardiotoxicities of paclitaxel in African Americans. 
  • Cardiovascular Complications of HIV in Endemic Countries. 
  • Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. 
  • Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. 
  • Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. 
  • Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). 
  • Cardiovascular effects and safety of dental anesthesia and dental interventions in patients with recent uncomplicated myocardial infarction. 
  • Cardiovascular effects of alcohol with particular reference to the heart. 
  • Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. 
  • Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. 
  • Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. 
  • Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. 
  • Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. 
  • Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. 
  • Care processes associated with quicker door-in-door-out times for patients with ST-elevation-myocardial infarction requiring transfer: results from a statewide regionalization program. 
  • Case-control study of thromboembolic events associated with IV immunoglobulin. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Caution in interpreting the findings from small observational studies. 
  • Cell therapy for heart failure: the need for a new therapeutic strategy. 
  • Central aortic pulse pressure, thrombogenicity and cardiovascular risk. 
  • Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. 
  • Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 
  • Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 
  • Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. 
  • Change in Angina Symptom Status After Acute Myocardial Infarction and Its Association With Readmission Risk: An Analysis of the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) Registry. 
  • Change in hospital-level use of transradial percutaneous coronary intervention and periprocedural outcomes: insights from the national cardiovascular data registry. 
  • Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. 
  • Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? 
  • Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. 
  • Changes in the production of IL-10 and TNF-alpha in skeletal muscle of rats with heart failure secondary to acute myocardial infarction. 
  • Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. 
  • Changing PR interval in a patient with acute inferior myocardial infarction. 
  • Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. 
  • Changing the model of care for patients with acute coronary syndromes. 
  • Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). 
  • Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal function. 
  • Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. 
  • Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction undergoing an invasive strategy according to hemoglobin levels. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Characteristics and outcomes in patients undergoing percutaneous coronary intervention following cardiac arrest (from the NCDR). 
  • Characteristics of creatine kinase-MB and MB isoforms in serum after reperfusion in acute myocardial infarction. 
  • Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). 
  • Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). 
  • Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. 
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. 
  • Charting the course of clinical research: from an inspired past to a promising future. 
  • Chelation therapy and cardiovascular outcomes--in reply. 
  • Chest pain presenting as ischemic heart disease. Congenital absence of the pericardium. 
  • Chest pain self-management training for patients with coronary artery disease. 
  • Chlamydia pneumoniae and acute coronary syndrome. 
  • Chronic exposure to nicotine does not prevent neurocognitive decline after cardiac surgery. 
  • Chronic false aneurysms of the left ventricle: management revisited. 
  • Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. 
  • Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. 
  • Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention. 
  • Clinical Characteristics and Outcomes of Patients With Myocardial Infarction and Cardiogenic Shock Undergoing Coronary Artery Bypass Surgery: Data From The Society of Thoracic Surgeons National Database. 
  • Clinical Relevance of Rehospitalizations for Unstable Angina and Unplanned Revascularization Following Acute Myocardial Infarction. 
  • Clinical and angiographic findings in black patients with suspected coronary artery disease. 
  • Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. 
  • Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. 
  • Clinical applications of highly sensitive troponin assays. 
  • Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. 
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 
  • Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. 
  • Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. 
  • Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Clinical outcomes according to time to treatment. 
  • Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. 
  • Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. 
  • Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. 
  • Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study. 
  • Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. 
  • Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study. 
  • Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. 
  • Clinical outcomes with drug-eluting stents following atheroablation therapies. 
  • Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. 
  • Clinical perspectives on reperfusion injury in acute myocardial infarction. 
  • Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. 
  • Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Clinical risks of thrombolytic therapy. 
  • Clinical significance of abnormal T waves in patients with non-ST-segment elevation acute coronary syndromes. 
  • Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt. 
  • Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. 
  • Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. 
  • Clinical trial participation after myocardial infarction in a national cardiovascular data registry. 
  • Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome. 
  • Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. 
  • Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? 
  • Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. 
  • Clopidogrel efficacy and cigarette smoking status. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. 
  • Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. 
  • Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. 
  • Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. 
  • Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. 
  • Cognitive and Physical Function by Statin Exposure in Elderly Individuals Following Acute Myocardial Infarction. 
  • Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction. 
  • Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry. 
  • Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. 
  • Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). 
  • Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. 
  • Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. 
  • Combination of Goldman risk and initial cardiac troponin I for emergency department chest pain patient risk stratification. 
  • Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. 
  • Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 
  • Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. 
  • Combined TMR and mitral valve replacement via left thoracotomy. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). 
  • Combined isoenzyme analysis in the diagnosis of myocardial injury: application of electrophoretic methods for the detection and quantitation of the creatine phosphokinase MB isoenzyme. 
  • Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. 
  • Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we? 
  • Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. 
  • Commentary on selected aspects of cardioprotection. 
  • Comparative Efficacy of Coronary Revascularization Procedures for Multivessel Coronary Artery Disease in Patients With Chronic Kidney Disease. 
  • Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. 
  • Comparative cardiovascular safety of dementia medications: a cross-national study. 
  • Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. 
  • Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). 
  • Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry. 
  • Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics. 
  • Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. 
  • Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction. 
  • Comparative rates of resolution of QRS changes after operative and nonoperative acute myocardial infarcts. 
  • Comparative study of local and Karhunen-Loève-based ST-T indexes in recordings from human subjects with induced myocardial ischemia. 
  • Comparison between contrast-enhanced magnetic resonance imaging and Selvester QRS scoring system in estimating changes in infarct size between the acute and chronic phases of myocardial infarction. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of 180 degrees and 360 degrees data collection in thallium-20 1 imaging using single-photon emission computerized tomography (SPECT): concise communication. 
  • Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. 
  • Comparison of Long-Term Mortality of Patients Aged ≤40 Versus >40 Years With Acute Myocardial Infarction. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of amaurosis fugax and transient cerebral ischemia: a prospective clinical and arteriographic study. 
  • Comparison of an automated thrombolytic predictive instrument to both diagnostic software and an expert cardiologist for diagnosis of an ST elevation acute myocardial infarction. 
  • Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. 
  • Comparison of angioplasty with stenting in acute myocardial infarction. 
  • Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
  • Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. 
  • Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. 
  • Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). 
  • Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents: a systematic review and meta-analysis. 
  • Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. 
  • Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. 
  • Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. 
  • Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. 
  • Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome. 
  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes. 
  • Comparison of high- and low-intensity exercise training early after acute myocardial infarction. 
  • Comparison of high-resolution and standard ECG parameters of myocardial ischemia during PTCA. 
  • Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. 
  • Comparison of long-term (seven year) outcomes among patients undergoing percutaneous coronary revascularization with versus without stenting. 
  • Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). 
  • Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). 
  • Comparison of outcomes among moderate alcohol drinkers before acute myocardial infarction to effect of continued versus discontinuing alcohol intake after the infarct. 
  • Comparison of outcomes in patients aged <75, 75 to 84, and ≥ 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). 
  • Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. 
  • Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. 
  • Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry. 
  • Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. 
  • Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. 
  • Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. 
  • Comparison of self-expanding and balloon-expandable stents for the reduction of restenosis. 
  • Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). 
  • Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). 
  • Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplasty. 
  • Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. 
  • Comparison of the Selvester QRS scoring system applied on standard versus high-resolution electrocardiographic recordings. 
  • Comparison of the correlation of the Selvester QRS scoring system with cardiac contrast-enhanced magnetic resonance imaging-measured acute myocardial infarct size in patients with and without thrombolytic therapy. 
  • Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. 
  • Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. 
  • Comparison of time domain and frequency domain variables from the signal-averaged electrocardiogram: a multivariable analysis. 
  • Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). 
  • Comparison of two biventricular infarct patterns with respect to the infarct burden required to induce cardiogenic shock: An experimental study. 
  • Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. 
  • Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. 
  • Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. 
  • Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. 
  • Complications following total knee arthroplasty--does the anaesthetic technique make a difference? 
  • Components of Type A, hostility, and anger-in: relationship to angiographic findings. 
  • Composite outcomes in coronary bypass surgery versus percutaneous intervention. 
  • Compromised atrial coronary anatomy is associated with atrial arrhythmias and atrioventricular block complicating acute myocardial infarction. 
  • Computer-assisted quantification of myocardial reperfusion after primary percutaneous coronary intervention predicts functional and contrast-enhanced cardiovascular magnetic resonance outcomes in patients with ST-segment elevation myocardial infarction. 
  • Computerized serial comparison of electrocardiograms: program performance in myocardial infarction. 
  • Computerized tomographic appearance of evolving myocardial infarctions. 
  • Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 
  • Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. 
  • Connecting the pieces of the cardiovascular care puzzle in Canada. 
  • Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention. 
  • Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. 
  • Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. 
  • Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). 
  • Consideration of the impact of reperfusion therapy on the quantitative relationship between the Selvester QRS score and infarct size by cardiac MRI. 
  • Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. 
  • Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. 
  • Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). 
  • Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). 
  • Contemporary pharmacological reperfusion in ST elevation myocardial infarction. 
  • Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry®-Get With The Guidelines (GWTG)®. 
  • Contemporary therapy of acute ST-elevation myocardial infarction. 
  • Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States. 
  • Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. 
  • Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. 
  • Contextualizing Myocardial Infarction: Comorbidities and Priorities in Older Adults. 
  • Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. 
  • Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. 
  • Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. 
  • Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. 
  • Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. 
  • Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. 
  • Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Control Beliefs and Risk for Death, Stroke and Myocardial Infarction in Middle-aged and Older Adults: An Observational Study. 
  • Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. 
  • Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. 
  • Copeptin does not add diagnostic information to high-sensitivity troponin T in low- to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) study. 
  • Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). 
  • Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. 
  • Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. 
  • Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. 
  • Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. 
  • Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. 
  • Coronary artery occlusion secondary to graft versus host disease after bone marrow transplant in a 21-year-old. 
  • Coronary bypass grafting after failed elective and failed emergent percutaneous angioplasty. Relative risks of emergent surgical intervention. 
  • Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Coronary collateral blood flow in acute myocardial infarction. 
  • Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry). 
  • Coronary cyclic flow variations following primary angioplasty is associated with poor short-term prognosis. 
  • Coronary embolism and calcified aortic valve: is there a correlation? 
  • Coronary intervention for persistent occlusion after myocardial infarction. 
  • Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. 
  • Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. 
  • Coronary reperfusion: numerators searching for denominators. 
  • Coronary revascularization after thrombolytic therapy for myocardial infarction: what caseloads could Canadian centres face? 
  • Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Correction of anemia with epoetin alfa in chronic kidney disease. 
  • Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. 
  • Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. 
  • Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction. 
  • Correlation of postmortem anatomic findings with electrocardiographic changes in patients with myocardial infarction: retrospective study of patients with typical anterior and posterior infarcts. 
  • Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. 
  • Correlations between preprocedure mood and clinical outcome in patients undergoing coronary angioplasty. 
  • Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. 
  • Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. 
  • Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. 
  • Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. 
  • Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. 
  • Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. 
  • Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. 
  • Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. 
  • Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group. 
  • Creation of pseudo narrowing during coronary angioplasty. 
  • Criteria for early discharge after acute myocardial infarction: validation in a community hospital. 
  • Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. 
  • Current State of Radial Artery Catheterization in ST-Elevation Myocardial Infarction. 
  • Current advances in the use of therapeutic hypothermia. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current quality of cardiovascular prevention for Million Hearts: an analysis of 147,038 outpatients from The Guideline Advantage. 
  • Current status of cardiac surgery in the abciximab-treated patient. 
  • Cyclic coronary flow: defining preinfarction angina at the crossroads of unstable angina and myocardial infarction. 
  • Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. 
  • Cytochrome P450 2C19 polymorphism and clopidogrel after MI. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Darapladib for preventing ischemic events in stable coronary heart disease. 
  • De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. 
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 
  • Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. 
  • Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. 
  • Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 
  • Defining myocardial infarction: a work in progress: Ischaemic heart disease. 
  • Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. 
  • Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction. 
  • Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. 
  • Delayed myocardial preconditioning by alpha1-adrenoceptors involves inhibition of apoptosis. 
  • Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. 
  • Delirium tremens in acute myocardial infarction. 
  • Dementia: a barrier to receiving percutaneous coronary intervention for elderly patients with ST-elevated myocardial infarction. 
  • Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Depression after myocardial infarction. 
  • Depression and five year survival following acute myocardial infarction: a prospective study. 
  • Depression and heart failure in patients with a new myocardial infarction. 
  • Depression and ischemic heart disease. 
  • Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. 
  • Depression and survival following myocardial infarction. 
  • Depression as a risk factor for mortality after acute myocardial infarction. 
  • Depression as a risk factor for post-MI mortality. 
  • Depression in elderly hospitalized patients with medical illness. 
  • Depression in patients with coronary artery disease. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Depression, heart rate variability, and acute myocardial infarction. 
  • Design and methodology of the Occluded Artery Trial (OAT). 
  • Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. 
  • Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. 
  • Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. 
  • Design of a modular, extensible decision support system for arrhythmia therapy. 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction. 
  • Detecting clinically meaningful biomarkers with repeated measurements: An illustration with electronic health records. 
  • Detection and characteristics of microvascular obstruction in reperfused acute myocardial infarction using an optimized protocol for contrast-enhanced cardiovascular magnetic resonance imaging. 
  • Detection of acute myocardial infarction using the 12-lead ECG plus inverted leads versus the 16-lead ECG (with additional posterior and right-sided chest electrodes). 
  • Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients. 
  • Detection, characterization and functional assessment of reperfused Q-wave acute myocardial infarction by cine magnetic resonance imaging. 
  • Deterioration of regional wall motion immediately after coronary artery bypass graft surgery is associated with long-term major adverse cardiac events. 
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. 
  • Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. 
  • Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress. 
  • Determining the cost economic "tipping point" for the addition of a regional percutaneous coronary intervention facility. 
  • Determining the most appropriate components for a composite clinical trial outcome. 
  • Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. 
  • Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. 
  • Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. 
  • Development of a serial comparison program for conduction defects, acute myocardial infarction, and the use of additional leads. 
  • Development of an automated Selvester Scoring System for estimating the size of myocardial infarction from the electrocardiogram. 
  • Development of systems of care for ST-elevation myocardial infarction patients: evaluation and outcomes. 
  • Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications. 
  • Development of systems of care for ST-elevation myocardial infarction patients: the primary percutaneous coronary intervention (ST-elevation myocardial infarction-receiving) hospital perspective. 
  • Diabetes Mellitus with Chronic Complications in Relation to Carotid Endarterectomy and Carotid Artery Stenting Outcomes. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. 
  • Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the national registry of myocardial infarction. 
  • Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. 
  • Diabetes status and racial differences in post-myocardial infarction mortality. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Diagnosing acute myocardial infarction in patients with left bundle branch block. 
  • Diagnosis and treatment of acute coronary ischemic syndromes: a update for 1995. 
  • Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive cardiac troponin I assay in patients with acute coronary syndrome. 
  • Diagnostic and prognostic significance of electrocardiographic and CPK isoenzyme changes following coronary bypass surgery: correlation with findings at one year. 
  • Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. 
  • Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. 
  • Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. 
  • Diagnostic problem in acute myocardial infarction: CK-MB in the absence of abnormally elevated total creatine kinase levels. 
  • Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: a report from the American Heart Association Mission: Lifeline program. 
  • Diastolic dysfunction: old dog, new tricks. 
  • Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. 
  • Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. 
  • Differences between chest pain observation service patients and admitted "rule-out myocardial infarction" patients. 
  • Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. 
  • Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy). 
  • Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. 
  • Differences in care-seeking behavior for acute chest pain in the United States and Japan. 
  • Differences in late cardiovascular mortality following acute myocardial infarction in three major Asian ethnic groups. 
  • Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of American College of Cardiology/American Heart Association Guidelines (CRUSADE). 
  • Differences in symptom presentation and hospital mortality according to type of acute myocardial infarction. 
  • Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. 
  • Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. 
  • Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial. 
  • Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry-GWTG. 
  • Differences in types A and B behavior in response to acute myocardial infarction. 
  • Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. 
  • Differentiation of viable and nonviable myocardium by the use of three-dimensional tagged MRI in 2-day-old reperfused canine infarcts. 
  • Dimensions of social support and depression in patients at increased psychosocial risk recovering from myocardial infarction. 
  • Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. 
  • Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary artery lesions: results from a randomized multicenter trial. The CAVEAT-I investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. 
  • Dissociation between hospital performance of the smoking cessation counseling quality metric and cessation outcomes after myocardial infarction. 
  • Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
  • Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. 
  • Distinct cardioprotective mechanisms of immediate, early and delayed ischaemic postconditioning. 
  • Distinct mouse coronary anatomy and myocardial infarction consequent to ligation. 
  • Distinguishing between early and late responders to symptoms of acute myocardial infarction. 
  • Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • Do cardiac troponins provide prognostic insight in hemodialysis patients? 
  • Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction? 
  • Do the investigative sites that take part in a positive clinical trial translate that evidence into practice? 
  • Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. 
  • Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. 
  • Does ICD therapy benefit women with a history of myocardial infarction and severe left ventricular dysfunction? 
  • Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? 
  • Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? 
  • Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. 
  • Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. 
  • Does ranolazine have a place in the treatment of acute coronary syndromes? 
  • Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. 
  • Does the early hazard phenomenon exist? Do the GUSTO findings prove or disprove? 
  • Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. 
  • Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. 
  • Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. 
  • Door-to-balloon time and mortality among patients undergoing primary PCI. 
  • Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the national cardiovascular data registry. 
  • Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. 
  • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 
  • Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. 
  • Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. 
  • Drug-eluting stents in acute myocardial infarction: is science catching up with practice? 
  • Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. 
  • Drug-eluting versus bare metal stenting in acute myocardial infarction. A clinical review. 
  • Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. 
  • Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. 
  • Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. 
  • Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. 
  • Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. 
  • Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. 
  • ECG interpretation in ST-elevation myocardial infarction: pattern recognition or caliper measurements? 
  • ECG myocardial infarct size: a gender-, age-, race-insensitive 12-segment multiple regression model. I: Retrospective learning set of 100 pathoanatomic infarcts and 229 normal control subjects. 
  • ECG quantification of myocardial scar and risk stratification in MADIT-II. 
  • ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. 
  • EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. 
  • ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 
  • ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. 
  • Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). 
  • Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. 
  • Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. 
  • Early detection of acute myocardial infarction: additional diagnostic information from serum concentrations of myoglobin in patients without ST elevation. 
  • Early discharge after acute myocardial infarction. 
  • Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. 
  • Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Early electrocardiographic diagnosis of acute myocardial infarction in the presence of ventricular paced rhythm. GUSTO-I investigators. 
  • Early exercise training in patients older than age 65 years compared with that in younger patients after acute myocardial infarction or coronary artery bypass grafting. 
  • Early hospital discharge after uncomplicated acute myocardial infarction. 
  • Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible? 
  • Early mortality of acute myocardial infarction in patients with and without prior coronary revascularization surgery. A Coronary Artery Surgery Study Registry Study. 
  • Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Early repolarization: a sword in the haystack? 
  • Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. 
  • Early statin initiation and outcomes in patients with acute coronary syndromes. 
  • Early sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Early treatment with intravenous metoprolol for suspected acute myocardial infarction: a phase IV United States trial. Phase IV Metoprolol in Myocardial Infarction Study Group. 
  • Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. 
  • Early versus delayed invasive intervention in acute coronary syndromes. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. 
  • Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR. 
  • Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. 
  • Echocardiographically detected myocardial infarction in the mouse. 
  • Echocardiography for the assessment of myocardial viability. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. 
  • Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. 
  • Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump. 
  • Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. 
  • Editorial: Data bank use in management of chronic disease. 
  • Editorial: Diagnostic considerations in electromechanical dissociation. 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. 
  • Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of anger provocation on endothelium-dependent and -independent vasodilation. 
  • Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. 
  • Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 
  • Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. 
  • Effect of cuts in Medicare reimbursement on process and outcome of care for acute myocardial infarction patients. 
  • Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). 
  • Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. 
  • Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. 
  • Effect of estrogen replacement therapy on corrected thrombolysis in myocardial infarction frame count. 
  • Effect of gender on the outcomes of contemporary percutaneous coronary intervention. 
  • Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). 
  • Effect of home testing of international normalized ratio on clinical events. 
  • Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts. 
  • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. 
  • Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. 
  • Effect of niacin on atherosclerotic cardiovascular disease. 
  • Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. 
  • Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). 
  • Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effect of smoking status on response to thrombolytic therapy. 
  • Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effect of the Presence and Type of Angina on Cardiovascular Events in Patients Without Known Coronary Artery Disease Referred for Elective Coronary Angiography. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. 
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. 
  • Effect on treatment delay of prehospital teletransmission of 12-lead electrocardiogram to a cardiologist for immediate triage and direct referral of patients with ST-segment elevation acute myocardial infarction to primary percutaneous coronary intervention. 
  • Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. 
  • Effectiveness of prehospital wireless transmission of electrocardiograms to a cardiologist via hand-held device for patients with acute myocardial infarction (from the Timely Intervention in Myocardial Emergency, NorthEast Experience [TIME-NE]). 
  • Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. 
  • Effects of Aerobic Cycling Training on O2 Dynamics in Several Leg Muscles in Early Post-myocardial Infarction. 
  • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. 
  • Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction. 
  • Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. 
  • Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 
  • Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. 
  • Effects of age and gender on the relationship between anxiety and coronary artery disease. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). 
  • Effects of body surface area-indexed calculations in the morbidly obese: a mathematical analysis. 
  • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 
  • Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. 
  • Effects of depression on QT interval variability after myocardial infarction. 
  • Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. 
  • Effects of exercise training on ventricular function in patients with recent myocardial infarction. 
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 
  • Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. 
  • Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. 
  • Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. 
  • Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine. 
  • Effects of myocardial infarction on the distribution and transport of nutrients and oxygen in porcine myocardium. 
  • Effects of perioperative statin use on cardiovascular complications in patients submitted to non-cardiac surgery: protocol for a systematic review, meta-analysis, and trial sequential analysis. 
  • Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. 
  • Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. 
  • Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. 
  • Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. 
  • Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. 
  • Effects of socioeconomic status on mortality after acute myocardial infarction. 
  • Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. 
  • Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. 
  • Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. 
  • Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. 
  • Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. 
  • Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. 
  • Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. 
  • Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (Hemagglutinating Virus of Japan)--liposome method. 
  • Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) 
  • Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. 
  • Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 
  • Electrocardiographic and hemodynamic correlations in patients with idiopathic hypertrophic subaortic stenosis. 
  • Electrocardiographic comparison of myocardial salvage with primary revascularization versus thrombolysis in inferior myocardial infarction. 
  • Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. 
  • Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of nonocclusive etiologies. 
  • Electrocardiographic factors playing a role in ischemic ventricular fibrillation in ST elevation myocardial infarction are related to the culprit artery. 
  • Electrocardiographic identification of the culprit coronary artery in inferior wall ST elevation myocardial infarction. 
  • Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. 
  • Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. 
  • Electrocardiographic methods for quantifying the sizes of healed infarction and acutely ischemic myocardium. 
  • Electrocardiographic phasing of acute myocardial infarction. 
  • Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial. 
  • Electrophysiologic properties of the myocardial infarction border zone: effects of transient aortic occlusion. 
  • Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. 
  • Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. 
  • Elevated skeletal muscle creatine kinase MB isoenzyme levels in marathon runners. 
  • Elevation in serum troponin I predicts the benefit of tirofiban. 
  • Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. 
  • Emergence of Collagen Orientation Heterogeneity in Healing Infarcts and an Agent-Based Model. 
  • Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. 
  • Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Emotional responsivity and transient myocardial ischemia. 
  • Emotional triggering of cardiac dysfunction: the present and future. 
  • End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. 
  • Endocardial fibroelastosis with coronary artery thromboembolus and myocardial infarction. 
  • Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. 
  • Endurance exercise in the presence of heart disease. 
  • Endurance training modulates lymphocyte function in rats with post-MI CHF. 
  • Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. 
  • Enhanced external counterpulsation in the management of patients with cardiovascular disease. 
  • Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. 
  • Enhancement of an old diagnostic tool, the standard 12-lead ECG. 
  • Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. 
  • Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. 
  • Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. 
  • Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. 
  • Enoxaparin vs unfractionated heparin in acute coronary syndrome. 
  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 
  • Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. 
  • Eplerenone in patients with acute myocardial infarction complicated by heart failure. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. 
  • Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. 
  • Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. 
  • Estimating the likelihood of significant coronary artery disease. 
  • Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. 
  • Evaluation of Cardiac Magnetic Resonance as a Surrogate in ST-Segment Elevation Myocardial Infarction. 
  • Evaluation of T-Wave Morphology in Patients With Left Bundle Branch Block and Suspected Acute Coronary Syndrome. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. II. Correlation with quantitative anatomic findings for anterior infarcts. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. III. Correlation with quantitative anatomic findings for inferior infarcts. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. IV. Correlation with quantitative anatomic findings for posterolateral infarcts. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. VI: Identification of screening criteria for non-acute myocardial infarcts. 
  • Evaluation of a QRS scoring system for estimating myocardial infarct size. VIII. Specificity in a control group with left ventricular hypertrophy and proposal of a new scoring system for use with this confounding factor. 
  • Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 
  • Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. 
  • Evaluation of asynergy as an indicator of myocardial fibrosis. 
  • Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. 
  • Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. 
  • Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction: a comparison of a multimarker panel to troponin alone and to testing in the central laboratory. 
  • Evaluation of formulas for estimating the final size of acute myocardial infarcts from quantitative ST-segment elevation on the initial standard 12-lead ECG. 
  • Evaluation of myocardial viability by MRI. 
  • Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. 
  • Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. 
  • Evaluation of serial QRS changes during acute inferior myocardial infarction using a QRS scoring system. 
  • Evaluation of the left ventricle with two dimensional echocardiography. 
  • Evaluation of vectorcardiographic criteria for the diagnosis of myocardial infarction in the presence of left ventricular hypertrophy. 
  • Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. 
  • Evidence for overturning the guidelines in cardiogenic shock. 
  • Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. 
  • Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. 
  • Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. 
  • Evidence-based care for all patients. 
  • Evidence-based perspectives on pay for performance and quality of patient care and outcomes in emergency medicine. 
  • Evolution and transmural distribution of collateral blood flow in acute myocardial infarction. 
  • Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. 
  • Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion. 
  • Evolution of electrocardiographic and echocardiographic abnormalities during the 4 years following first acute myocardial infarction. 
  • Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. 
  • Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. 
  • Evolving non-Q wave versus Q wave myocardial infarction after thrombolysis: a high risk population benefitting from early revascularization. A DANAMI substudy. 
  • Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. 
  • Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. 
  • Exercise stress testing in evaluation of aortocoronary bypass surgery. Report of 123 patients. 
  • Exercise training changes IL-10/TNF-alpha ratio in the skeletal muscle of post-MI rats. 
  • Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. 
  • Exercise, depression, and mortality after myocardial infarction in the ENRICHD trial. 
  • Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. 
  • Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. 
  • Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. 
  • Expected and realized benefits from coronary bypass surgery in relation to severity of illness. 
  • Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes. 
  • Experience with the use of tPA in the treatment of acute myocardial infarction. 
  • Experimental infarct size as a function of the amount of myocardium at risk. 
  • Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. 
  • Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). 
  • Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 
  • Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove! 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitated versus primary PCI for acute myocardial infarction. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction. 
  • Factors associated with delay in giving thrombolytic therapy after arrival at hospital. 
  • Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. 
  • Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. 
  • Factors associated with ventricular inducibility in the MADIT-II study population. 
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. 
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. 
  • Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. 
  • Failure of thrombin generation markers to triage patients presenting with chest pain. 
  • Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry. 
  • False aneurysm of the aortic root: mimic of malignancy, mediator of myocardial ischemia. 
  • False-positive posterior myocardial infarct criteria during left anterior descending coronary angioplasty. 
  • Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. 
  • Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). 
  • Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. 
  • Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group. 
  • Feasibility and applicability of computer-assisted myocardial blush quantification after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Feasibility and safety of combined percutaneous coronary intervention and therapeutic hypothermia following cardiac arrest. 
  • Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolysis or primary PCI in myocardial infarction. 
  • Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. 
  • Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates. 
  • Fine particulate matter and cardiovascular disease: Comparison of assessment methods for long-term exposure. 
  • First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. 
  • First successful bridge to cardiac transplantation using direct mechanical ventricular actuation. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model. 
  • Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. 
  • Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? 
  • Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. 
  • For how long should treatment with clopidogrel be continued after coronary stent implantation? 
  • Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. 
  • Found in translation soluble ST2 and heart disease. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. 
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). 
  • Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. 
  • Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program). 
  • Frequency of transient reductions in left ventricular ejection fraction at rest in coronary artery disease. 
  • Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • From ST-elevation myocardial infarction to ST elevation with no myocardial infarction--review and overview of a new horizon of computerized electrocardiographic ischemia detection using high-fidelity implantable devices. 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. 
  • From theory to practice: implementation of pre-hospital electrocardiogram transmission in ST-elevation myocardial infarction - a multicenter experience. 
  • From thrombolytic megatrials to clinical policy-making: facing the facts. 
  • Frontiers in cardiovascular magnetic resonance. 
  • Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. 
  • Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough. 
  • G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. 
  • Galectin-3 expression in cardiac remodeling after myocardial infarction. 
  • Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States. 
  • Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gated resting Tl-201 SPECT in the evaluation of myocardial viability. 
  • Gender and acute myocardial infarction: is there a different response to thrombolysis? 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Gender differences in postinfarction left ventricular remodeling. 
  • Gender differences in the link between childhood socioeconomic conditions and heart attack risk in adulthood. 
  • Gender differences in the treatment of non-ST-segment elevation myocardial infarction. 
  • Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). 
  • Gender-specific 30-day outcomes after carotid endarterectomy and carotid artery stenting in the Society for Vascular Surgery Vascular Registry. 
  • Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. 
  • Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. 
  • Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. 
  • Genetic and functional association of FAM5C with myocardial infarction. 
  • Genetic engineering and stem cells: combinatorial approaches for cardiac cell therapy. 
  • Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. 
  • Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. 
  • Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium. 
  • Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. 
  • Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. 
  • Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery. 
  • Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. 
  • Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. 
  • Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. 
  • Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. 
  • Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. 
  • Glycoprotein IIb/IIIa inhibitors and the guidelines for treatment of non-ST-elevation myocardial infarction. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 
  • Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. 
  • Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. 
  • Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. 
  • Grade 3 ischemia on the admission electrocardiogram predicts rapid progression of necrosis over time and less myocardial salvage by primary angioplasty. 
  • Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. 
  • Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group. 
  • Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. 
  • Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. 
  • Guidelines for STEMI. 
  • Guidelines for exercise therapy of the elderly after myocardial infarction. 
  • Guidelines for risk stratification after myocardial infarction. American College of Physicians. 
  • Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. 
  • HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. 
  • HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. 
  • HEART Failure? Episodes of Missed Major Cardiac Events When Applying the HEART Pathway to an Observation Unit Population. 
  • Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motion. 
  • Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?: Analysis of Medicare Claims Data. 
  • Have we made progress in reducing time to reperfusion in the management of acute myocardial infarction? A last decade overview. The potential key role of wireless electrocardiographic transmission. 
  • Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. 
  • Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. 
  • Heart attack. 
  • Heart disease epidemic in Pakistan: women and men at equal risk. 
  • Heart failure after myocardial infarction: A good heart is hard to find. 
  • Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. 
  • Heart fatty acid binding protein as a marker for postmortem detection of early myocardial damage. 
  • Heart rate turbulence, depression, and survival after acute myocardial infarction. 
  • Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. 
  • Helicopter transport of patients during acute myocardial infarction. 
  • Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. 
  • Hemodynamic findings in 123 patients with acute myocardial infarction on admission. 
  • Hemoglobin S-nitrosylation plays an essential role in cardioprotection. 
  • Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. 
  • Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. 
  • Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. 
  • Hemorrhagic pericardial effusion following myocardial infarction associated with a ventricular aneurysm. 
  • Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. 
  • Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Heparin in acute coronary disease--requiem for a heavyweight? 
  • Heparin management in acute myocardial infarction (AMI). 
  • Heparin versus hirudin for acute coronary syndromes. 
  • Heparin-coated stents do not protect cancer patients from cardiac complications after noncardiac surgery. 
  • Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation. 
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. 
  • Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. 
  • Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. 
  • High prevalence of lack of knowledge of symptoms of acute myocardial infarction in Pakistan and its contribution to delayed presentation to the hospital. 
  • High temporal resolution breathheld 3D FIESTA CINE imaging: validation of ventricular function in patients with chronic myocardial infarction. 
  • High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. 
  • High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. 
  • High-resolution imaging of murine myocardial infarction with delayed-enhancement cine micro-CT. 
  • High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. 
  • High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. 
  • High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. 
  • Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. 
  • Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). 
  • Histopathologic examination of material from angioplasty balloon catheters used in vivo in human coronary arteries. 
  • History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke. 
  • History of depression and survival after acute myocardial infarction. 
  • Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Home use of automated external defibrillators for sudden cardiac arrest. 
  • Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. 
  • Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. 
  • Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry. 
  • Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. 
  • Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. 
  • Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. 
  • Hospital-acquired anemia and in-hospital mortality in patients with acute myocardial infarction. 
  • Hostility, CHD incidence, and total mortality: a 25-year follow-up study of 255 physicians. 
  • How Reliable are Patient-Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies. 
  • How best to monitor for detection of myocardial ischemia? 
  • How can we optimize the processes of care for acute coronary syndromes to improve outcomes? 
  • How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. 
  • How much do we gain by reducing time to reperfusion therapy? 
  • How should clinicians interpret clinical trials? 
  • How we perform delayed enhancement imaging. 
  • Hydrops fetalis associated with idiopathic arterial calcification. 
  • Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction. 
  • Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. 
  • Hypertensive retinopathy and incident coronary heart disease in high risk men. 
  • Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". 
  • ISIS-4. 
  • Identification and treatment of low-risk patients after acute myocardial infarction and coronary-artery bypass graft surgery. 
  • Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. 
  • Identification of the optimal electrocardiographic leads for detecting acute epicardial injury in acute myocardial infarction. 
  • Identification of variables needed to risk adjust outcomes of coronary interventions: evidence-based guidelines for efficient data collection. 
  • Identifying high-quality hospitals: consult the ratings or flip a coin? 
  • Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. 
  • Idiopathic facial nerve paralysis and acute myocardial infarction. 
  • Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. 
  • Immediate and remote prognostic significance of fascicular block during acute myocardial infarction. 
  • Immediate versus delayed coronary grafting after streptokinase treatment. Postoperative blood loss and clinical results. 
  • Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Impact of Balloon Predilatation on Hemodynamics and Outcomes After Transcatheter Aortic Valve Implantation With the Self-Expanding CoreValve Prosthesis. 
  • Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSLATE-ACS. 
  • Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. 
  • Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. 
  • Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. 
  • Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis. 
  • Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. 
  • Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderly. 
  • Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. 
  • Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). 
  • Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. 
  • Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Impact of case volume on hospital performance assessment. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. 
  • Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 
  • Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction. 
  • Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). 
  • Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. 
  • Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. 
  • Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. 
  • Impact of early, late, and no ST-segment resolution measured by continuous ST Holter monitoring on left ventricular ejection fraction and infarct size as determined by cardiovascular magnetic resonance imaging. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). 
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia. 
  • Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. 
  • Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. 
  • Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). 
  • Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. 
  • Impact of medication therapy discontinuation on mortality after myocardial infarction. 
  • Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. 
  • Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. 
  • Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. 
  • Impact of percutaneous coronary intervention performance reporting on cardiac resuscitation centers: a scientific statement from the American Heart Association. 
  • Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). 
  • Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. 
  • Impact of race on cardiac care and outcomes in veterans with acute myocardial infarction. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. 
  • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. 
  • Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). 
  • Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program. 
  • Impact of time of presentation on the care and outcomes of acute myocardial infarction. 
  • Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). 
  • Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. 
  • Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. 
  • Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. 
  • Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. 
  • Implementation of Regional ST-Segment Elevation Myocardial Infarction Systems of Care: Successes and Challenges. 
  • Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. 
  • Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. 
  • Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. 
  • Implications of High-Sensitivity Troponin Testing: Learning From Those Who Came Before Us. 
  • Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. 
  • Implications of family history of myocardial infarction in young women. 
  • Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. 
  • Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. 
  • Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream". 
  • Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Importance of an intact growth hormone/insulin-like growth factor 1 axis for normal post-infarction healing: studies in dwarf rats. 
  • Importance of cost and quality of life in decisions about routine angiography after acute myocardial infarction. The role of cost-effectiveness models. 
  • Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. 
  • Importance of electrocardiography for coronary risk factor surveys. 
  • Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Importance of papillary muscle infarction detected by cardiac magnetic resonance imaging in predicting cardiovascular events. 
  • Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. 
  • Important patient subgroups in thrombolytic therapy. 
  • Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. 
  • Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT. 
  • Improved outlook for patients with acute myocardial infarction: an interim progress report. 
  • Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. 
  • Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. 
  • Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 
  • Improvement in quality indicators using NCDR® registries: First international experience. 
  • Improvements in quality improvement. 
  • Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. 
  • Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. 
  • Improving integrated care in low- and middle-income countries: the final STEMI frontier? 
  • Improving outcomes in patients with cardiogenic shock: achieving more through less. 
  • Improving outcomes in primary percutaneous coronary intervention: Transradial is worth the time. 
  • Improving quality of life after cardiogenic shock: do more revascularization! 
  • Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. 
  • In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. 
  • In vivo assessment of left ventricular remodelling after myocardial infarction by digital video contrast angiography in the rat. 
  • In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. 
  • In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. 
  • In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. 
  • In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. 
  • In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. 
  • Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. 
  • Incidence and clinical relevance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. 
  • Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. 
  • Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. 
  • Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. 
  • Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. 
  • Incidence of caffeine in serum of patients undergoing dipyridamole myocardial perfusion stress test by an intensive versus routine caffeine history screening. 
  • Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. 
  • Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. 
  • Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. 
  • Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. 
  • Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. 
  • Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. 
  • Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. 
  • Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. 
  • Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. 
  • Incorporation of a left ventricle finite element model defining infarction into the XCAT imaging phantom. 
  • Increase in ST-segment elevation immediately after reperfusion: cause and meaning. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. 
  • Increased plasma propranolol binding in myocardial infarction. 
  • Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. 
  • Incremental benefit of 80-lead electrocardiogram body surface mapping over the 12-lead electrocardiogram in the detection of acute coronary syndromes in patients without ST-elevation myocardial infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) trial. 
  • Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. 
  • Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group. 
  • Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? 
  • Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. 
  • Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. 
  • Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study. 
  • Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. 
  • Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms. 
  • Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors. 
  • Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. 
  • Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. 
  • Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. 
  • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. 
  • Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. 
  • Influence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes. 
  • Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. 
  • Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction. 
  • Influence of the location of left anterior descending coronary artery stenosis on left ventricular function during exercise. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. 
  • Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction. 
  • Influences of electrocardiographic ischaemia grades and symptom duration on outcomes in patients with acute myocardial infarction treated with thrombolysis versus primary percutaneous coronary intervention: results from the DANAMI-2 trial. 
  • Informational Quest. 
  • Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 
  • Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. 
  • Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. 
  • Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. 
  • Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions. 
  • Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. 
  • Inpatient and follow-up cardiology care and mortality for acute coronary syndrome patients in the Veterans Health Administration. 
  • Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. 
  • Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? 
  • Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction. 
  • Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. 
  • Interactive associations of depression and sleep apnea with adverse clinical outcomes after acute myocardial infarction. 
  • International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. 
  • International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries. 
  • International differences in evolution of early discharge after acute myocardial infarction. 
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. 
  • International variation in and factors associated with hospital readmission after myocardial infarction. 
  • Intervening on small infarct-related arteries: what does the future hold? 
  • Interventional cardiac catheterization at Duke Medical Center. 
  • Interventional cardiac catheterization. 
  • Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. 
  • Intra-aortic balloon counterpulsation reduces mortality in large anterior myocardial infarction complicated by persistent ischaemia: a CRISP-AMI substudy. 
  • Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. 
  • Intracardiac acoustic radiation force impulse (ARFI) and shear wave imaging in pigs with focal infarctions. 
  • Intracardiac transplantation of a mixed population of bone marrow cells improves both regional systolic contractility and diastolic relaxation. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. 
  • Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. 
  • Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. 
  • Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. 
  • Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. 
  • Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. 
  • Intraoperative detection of myocardial damage during coronary artery surgery by plasma creatine phosphokinase isoenzyme analysis. 
  • Intraoperative echocardiography is indicated in high-risk coronary artery bypass grafting. 
  • Intravascular ultrasound in the management of acute coronary artery dissection: a case report. 
  • Intravenous Beta-Blockers for Cardioprotection in STEMI: The Saga Continues. 
  • Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Intravenous platelet blockade with cangrelor during PCI. 
  • Intravenous thrombolysis in acute myocardial infarction. 
  • Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. 
  • Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death. 
  • Introduction: evidence to practice in acute coronary syndromes. 
  • Involuntary job loss as a risk factor for subsequent myocardial infarction and stroke: findings from the Health and Retirement Survey. 
  • Ionizing radiation exposure to patients admitted with acute myocardial infarction in the United States. 
  • Is chronically dysfunctional yet viable myocardium distal to a severe coronary stenosis hypoperfused? 
  • Is coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction? 
  • Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s? 
  • Is it possible to differentiate between Takotsubo cardiomyopathy and acute anterior ST-elevation myocardial infarction? 
  • Is it time for a randomized trial of surgical treatment of ischemic heart failure? 
  • Is silent myocardial infarction more common in women with type 2 diabetes than in men? 
  • Is the use of t-PA as compared with streptokinase cost effective? 
  • Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. 
  • Ischemic cardiomyopathy: the myopathy of coronary artery disease. Natural history and results of medical versus surgical treatment. 
  • Ischemic mitral regurgitation. 
  • It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction. 
  • Job characteristics in relation to the prevalence of myocardial infarction in the US Health Examination Survey (HES) and the Health and Nutrition Examination Survey (HANES). 
  • Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. 
  • Knowledge and Insights Vested in Us by the VEST. 
  • Knowledge of modifiable risk factors of heart disease among patients with acute myocardial infarction in Karachi, Pakistan: a cross sectional study. 
  • LDH isoenzymes and myocardial infarction in patients undergoing coronary bypass surgery: an excellent correlation. 
  • LEFT AXIS DEVIATION. 
  • Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. 
  • Larger infarct size and lower left ventricular ejection fraction (LVEF) contribute to the higher mortality in diabetic patients with ST elevation myocardial infarction. 
  • Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators) 
  • Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. 
  • Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Lateral MI Explains the Presence of Prominent R Wave (R ≥ S) in V1. 
  • Learned Helplessness and Depressive Symptoms Following Myocardial Infarction. 
  • Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction. 
  • Learning to suspect the unexpected: evaluating women with cardiac syndromes. 
  • Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. 
  • Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). 
  • Left ventricular assessment in myocardial infarction: the VALIANT registry. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Left ventricular ejection fraction after acute coronary occlusion in conscious dogs: relation to the extent and site of myocardial infarction. 
  • Left ventricular ejection fraction assessment among patients with acute myocardial infarction and its association with hospital quality of care and evidence-based therapy use. 
  • Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. 
  • Left ventricular functional assessment in mice: feasibility of high spatial and temporal resolution ECG-gated blood pool SPECT. 
  • Left ventricular hypertrophy impairs detection of myocardial infarction in patients with nonischemic cardiomyopathy. 
  • Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Letter by Januzzi regarding article, "galectin-3 and cardiac function in survivors of acute myocardial infarction". 
  • Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". 
  • Letter: Ventricular septal defect and mitral regurgitation secondary to myocardial infarction. 
  • Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. 
  • Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. 
  • Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. 
  • Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). 
  • Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction. 
  • Lipoprotein(a) and silent myocardial ischemia in IDDM. 
  • Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. 
  • Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. 
  • Localization of mesenchymal stem cells grafted with a hyaluronan-based scaffold in the infarcted heart. 
  • Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. 
  • Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. 
  • Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. 
  • Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction. 
  • Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). 
  • Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term clinical outcomes following coronary stenting. 
  • Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. 
  • Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. 
  • Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. 
  • Long-term outcome of patients with perioperative myocardial infarction as diagnosed by troponin I after routine surgical coronary artery revascularization. 
  • Long-term outcomes after carotid endarterectomy: can the past be used to predict the future? 
  • Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. 
  • Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. 
  • Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. 
  • Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. 
  • Long-term outcomes of the symmetry vein graft anastomosis device: a matched case-control analysis. 
  • Long-term prognosis and risk heterogeneity of heart failure complicating acute myocardial infarction. 
  • Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. 
  • Long-term survival from acute myocardial infarction: salutary effect of an open coronary vessel. 
  • Long-term trends in the incidence of heart failure after myocardial infarction. 
  • Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. 
  • Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. 
  • Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. 
  • Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. 
  • Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). 
  • Low heart rate variability and the effect of depression on post-myocardial infarction mortality. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery. 
  • Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease. 
  • Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. 
  • MADIT-II: clinical implications. 
  • MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. 
  • Macular degeneration and heart disease. 
  • Magnesium and myocardial infarction. 
  • Magnesium in acute myocardial infarction. 
  • Magnetic resonance imaging of chronic myocardial infarcts in formalin-fixed human autopsy hearts. 
  • Magnitude and Characteristics of Patients Who Survived an Acute Myocardial Infarction. 
  • Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Management of non-Q-wave myocardial infarction. 
  • Marital history and survival after a heart attack. 
  • Markers of cardiac ischemia, injury, and inflammation. 
  • Mathematical modifications fail to improve CPK estimates of extent of infarct. 
  • Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. 
  • Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. 
  • Maximum likelihood estimation of time to first event in the presence of data gaps and multiple events. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Measurement of Exercise Tolerance before Surgery (METS) study: a protocol for an international multicentre prospective cohort study of cardiopulmonary exercise testing prior to major non-cardiac surgery. 
  • Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. 
  • Measuring hospital mortality rates: are 30-day data enough? Ischemic Heart Disease Patient Outcomes Research Team. 
  • Measuring the effectiveness of medical care delivery. 
  • Mechanical Ventilation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Retrospective Observational Study. 
  • Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). 
  • Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. 
  • Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. 
  • Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. 
  • Mechanisms by which transradial approach may reduce mortality in ST-segment-elevation myocardial infarction. 
  • Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. 
  • Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction. 
  • Medical history for prognostic risk assessment and diagnosis of stable patients with suspected coronary artery disease. 
  • Medical treatment for stroke prevention. 
  • Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. 
  • Medication non-adherence after myocardial infarction: an exploration of modifying factors. 
  • Medication performance measures and mortality following acute coronary syndromes. 
  • Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction. 
  • Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. 
  • Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. 
  • Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. 
  • Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. 
  • Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. 
  • Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. 
  • Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. 
  • Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. 
  • Metabolic profiles predict adverse events after coronary artery bypass grafting. 
  • Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease. 
  • Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. 
  • Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. 
  • Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. 
  • Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. 
  • MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function. 
  • Microvascular dysfunction following primary percutaneous coronary intervention in the setting of ST-elevation myocardial infarction. 
  • Microvascular integrity and the time course of myocardial sodium accumulation after acute infarction. 
  • Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. 
  • Mild therapeutic hypothermia in patients after out-of-hospital cardiac arrest due to acute ST-segment elevation myocardial infarction. 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. 
  • Minimal myocardial damage during coronary intervention is associated with impaired outcome. 
  • Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group). 
  • Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? 
  • Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. 
  • Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. 
  • Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: implications for strategic management. 
  • Mode of induction of ventricular tachycardia and prognosis in patients with coronary disease: the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. 
  • Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry. 
  • Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. 
  • Modifying the mechanics of healing infarcts: Is better the enemy of good? 
  • Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. 
  • Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. 
  • More on the GUSTO Trial. 
  • Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 
  • Mortality after myocardial infarction: the role of renal function and systolic and diastolic functions of the left ventricle. 
  • Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. 
  • Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Mortality from ship emissions: a global assessment. 
  • Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. 
  • Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • Moving care forward: prehospital emergency cardiac systems. 
  • Moving from evidence to practice in the care of patients who have acute coronary syndrome. 
  • Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction. 
  • Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC consensus conference. European Society of Cardiology and American College of Cardiology. 
  • Moving troponin testing into the 21st century: will greater sensitivity be met with greater sensibility? 
  • Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial. 
  • Multi-scale heart rate dynamics detected by phase-rectified signal averaging predicts mortality after acute myocardial infarction. 
  • Multi-site Measurements of Muscle O2 Dynamics During Cycling Exercise in Early Post-myocardial Infarction. 
  • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. 
  • Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • Multicenter review of preoperative risk factors for carotid endarterectomy in patients with ipsilateral symptoms. 
  • Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. 
  • Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. 
  • Multiple Chronic Conditions in Older Adults with Acute Coronary Syndromes. 
  • Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry. 
  • Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. 
  • Munchausen's syndrome and cardiac catheterization. A case of a pernicious interaction. 
  • Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. 
  • Myocardial cell hypertrophy after myocardial infarction with reperfusion in dogs. 
  • Myocardial contractile reserve and perfusion defect severity with rest and stress dobutamine (99m)Tc-sestamibi SPECT in canine stunning and subendocardial infarction. 
  • Myocardial infarction and coronary artery dissection in pregnancy. 
  • Myocardial infarction and intramyocardial injection models in swine. 
  • Myocardial infarction and risk of suicide: another reason to develop and test ways to reduce distress in postmyocardial-infarction patients? 
  • Myocardial infarction and stroke. 
  • Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. 
  • Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. 
  • Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. 
  • Myocardial infarction rule-out in the emergency department: are high-sensitivity troponins the answer?: comment on "One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T". 
  • Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. 
  • Myocardial protection during coronary angioplasty with an autoperfusion balloon catheter in humans. 
  • Myocardial protection. 
  • Myocardial reperfusion injury. 
  • Myocardial reperfusion: is it ever too late? 
  • Myocardial salvage after failed coronary angioplasty. 
  • Myocardial salvage after reperfusion. Observations from analysis of serial electrocardiographic and biochemical indices. 
  • Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model. 
  • Myonecrosis after revascularization procedures. 
  • Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. 
  • Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction. 
  • N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. 
  • N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. 
  • NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. 
  • National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. 
  • Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program. 
  • Nationwide trends in the age adjusted prevalence of non-ST elevation myocardial infarction (NSTEMI) across various races and gender in the USA. 
  • Necessity of hospitalization and stress testing in low risk chest pain patients. 
  • Need for centers to care for patients with acute coronary syndromes. 
  • Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. 
  • Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. 
  • Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. 
  • Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. 
  • New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. 
  • New biomarkers in the risk stratification of patients with suspected acute myocardial infarction. 
  • New heparin dosing recommendations for patients with acute coronary syndromes. 
  • New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry). 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Nighttime heart rate and survival in depressed patients post acute myocardial infarction. 
  • Nitroglycerin ointment in acute myocardial infarction. 
  • No STEMI left behind. 
  • No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. 
  • No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. 
  • Nocturnal patterns of heart rate and the risk of mortality after acute myocardial infarction. 
  • Non-Q wave infarction after thrombolytic therapy. 
  • Non-Q wave myocardial infarction. Pathophysiology and prognostic implications. 
  • Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. 
  • Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. 
  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). 
  • Non-evidence-based ICD implantations in the United States. 
  • Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. 
  • Nonfatal myocardial infarction in medically treated patients with coronary artery disease. 
  • Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. 
  • Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. 
  • Noninvasive radionuclide procedures for diagnosis and management of myocardial ischemia. 
  • Nonobstructive chronic cannulation of the left circumflex coronary artery of the dog. 
  • Nonobstructive coronary artery disease and risk of myocardial infarction. 
  • Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. 
  • Nonsystem reasons for delay in door-to-balloon time and associated in-hospital mortality: a report from the National Cardiovascular Data Registry. 
  • Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. 
  • Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning. 
  • Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. 
  • Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. 
  • Obesity and age of first non-ST-segment elevation myocardial infarction. 
  • Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. 
  • Off-pump coronary bypass grafting is associated with less myocardial injury than coronary bypass surgery with cardiopulmonary bypass. 
  • Omega-3 fatty acids for secondary prevention. 
  • On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction. 
  • On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). 
  • On-line microcomputer system for analysis of precordial maps. 
  • One-year cardiovascular event rates in outpatients with atherothrombosis. 
  • One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I) 
  • One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. 
  • One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. 
  • One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). 
  • One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. 
  • One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. 
  • Opioid use for noncancer pain and risk of myocardial infarction amongst adults. 
  • Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). 
  • Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. 
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. 
  • Optimizing the science of quality improvement. 
  • Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. 
  • Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. 
  • Oral platelet glycoprotein IIb/IIIa inhibition. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. 
  • Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. 
  • Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 
  • Outcome of acute myocardial infarction according to the specialty of the admitting physician. 
  • Outcome of acute myocardial infarction according to the specialty of the admitting physician. 
  • Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. 
  • Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. 
  • Outcomes after acute coronary syndrome admission to primary versus tertiary Veterans Affairs medical centers: the Veterans Affairs Access to Cardiology study. 
  • Outcomes after coronary artery bypass grafting in patients with myocardial infarction, cardiogenic shock and unresponsive neurological state: analysis of the Society of Thoracic Surgeons Database. 
  • Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. 
  • Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). 
  • Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital. 
  • Outcomes for patients with ST-elevation myocardial infarction in hospitals with and without onsite coronary artery bypass graft surgery: the New York State experience. 
  • Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. 
  • Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. 
  • Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. 
  • Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device: A Comprehensive Review and Meta-Analysis. 
  • Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). 
  • Outcomes of acute myocardial infarction in the Department of Veterans Affairs: does regionalization of health care work? 
  • Outcomes of anatomical versus functional testing for coronary artery disease. 
  • Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. 
  • Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). 
  • Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. 
  • Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). 
  • Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. 
  • Outcomes of primary stenting for acute myocardial infarction. 
  • Outcomes of second revascularization procedures after stent implantation. 
  • Overcoming barriers to developing seamless ST-segment elevation myocardial infarction care systems in the United States: recommendations from a comprehensive Prehospital 12-lead Electrocardiogram Working Group. 
  • Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes. 
  • Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • P2X7 receptor agonists pre- and postcondition the heart against ischemia-reperfusion injury by opening pannexin-1/P2X₇ channels. 
  • PCI at non-PCI centres: immediate or rescue? 
  • Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study. 
  • Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. 
  • Paracrine mechanisms in adult stem cell signaling and therapy. 
  • Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. 
  • Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. 
  • Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. 
  • Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. 
  • Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Patient Portals: Who uses them? What features do they use? And do they reduce hospital readmissions? 
  • Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. 
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 
  • Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. 
  • Patient-centered outcomes composites: a glimpse of the future. 
  • Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. 
  • Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. 
  • Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). 
  • Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. 
  • Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. 
  • Patterns and outcomes of drug-eluting coronary stent use in clinical practice. 
  • Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. 
  • Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). 
  • Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative). 
  • Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). 
  • Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry. 
  • Pay for performance, quality of care, and outcomes in acute myocardial infarction. 
  • Peak CKMB and cTnT accurately estimates myocardial infarct size after reperfusion. 
  • Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. 
  • Pennsylvania's Focus on Heart Attack--grading the scorecard. 
  • Perceptions of advantages and barriers to radial-access percutaneous coronary intervention in VA cardiac catheterization laboratories. 
  • Percutaneous coronary intervention after ST-segment elevation myocardial infarction in nonagenarians: use rates and in-hospital mortality. 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Percutaneous coronary revascularisation: is it ever worth what it costs? 
  • Percutaneous transluminal coronary angioplasty as palliation for patients considered poor surgical candidates. 
  • Percutaneous transluminal coronary angioplasty in women compared with men. 
  • Performance of CMR Methods for Differentiating Acute From Chronic MI. 
  • Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction. 
  • Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. 
  • Performance of new criteria for right ventricular hypertrophy and myocardial infarction in patients with pulmonary hypertension due to cor pulmonale and mitral stenosis. 
  • Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. 
  • Performance of the automated complete Selvester QRS scoring system. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias. 
  • Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. 
  • Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Perioperative organ injury. 
  • Peripartum cardiomyopathy presenting as an acute myocardial infarction. 
  • Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. 
  • Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. 
  • Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications. 
  • Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. 
  • Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. 
  • Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. 
  • Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging. 
  • Perspectives gained from large-scale thrombolytic comparative trials. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pexelizumab and the APEX AMI trial. 
  • Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. 
  • Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. 
  • Pharmacogenetics of Clopidogrel: An Unresolved Issue. 
  • Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. 
  • Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death. 
  • Pharmacotherapy: Intracoronary streptokinase in acute myocardial infarction. 
  • Phobic anxiety and increased risk of mortality in coronary heart disease. 
  • Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. 
  • Physical function and independence 1 year after myocardial infarction: observations from the Translational Research Investigating Underlying disparities in recovery from acute Myocardial infarction: Patients' Health status registry. 
  • Physiological Implications of Myocardial Scar Structure. 
  • Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. 
  • Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. 
  • Pim1 Kinase Overexpression Enhances ckit+ Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine. 
  • Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. 
  • Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction. 
  • Platelet RNA as a novel biomarker for the response to antiplatelet therapy. 
  • Platelet activation and pneumonia: is soluble p-selectin the right marker? 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Platelet function monitoring in patients with coronary artery disease. 
  • Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. 
  • Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. 
  • Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. 
  • Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. 
  • Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet response in practice: Applying new insights and tools for testing and treatment. 
  • Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. 
  • Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction. 
  • Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. 
  • Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. 
  • Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. 
  • Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. 
  • Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. 
  • Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility? 
  • Post-myocardial infarction risk stratification in elderly patients. 
  • Post-myocardial infarction smoking cessation counseling: associations with immediate and late mortality in older Medicare patients. 
  • Postcoronary thrombolysis management. 
  • Postinfarction ventricular septal defects: surgical or percutaneous closure-between a rock and a hard place. 
  • Postmenopausal hormone use in women with acute coronary syndromes. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. 
  • Potential unintended financial consequences of pay-for-performance on the quality of care for minority patients. 
  • Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. 
  • Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. 
  • Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program. 
  • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
  • Prasugrel versus clopidogrel for acute coronary syndromes. 
  • Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. 
  • Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. 
  • Pre-existing major depression predicts in-hospital cardiac complications after acute myocardial infarction. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Pre-operative coronary revascularization: an optimal therapy for high-risk vascular surgery patients? 
  • Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. 
  • Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction. 
  • Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. 
  • Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. 
  • Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Predicting complications of carotid endarterectomy. 
  • Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. 
  • Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. 
  • Predicting major adverse cardiac events in spine fusion patients: is the revised cardiac risk index sufficient? 
  • Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. 
  • Predicting perioperative cardiac risk. 
  • Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. 
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. 
  • Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. 
  • Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. 
  • Prediction of death and myocardial infarction by radionuclide angiocardiography in patients with suspected coronary artery disease. 
  • Prediction of death and nonfatal myocardial infarction in high-risk patients: a comparison between the Duke treadmill score, peak exercise radionuclide angiography, and SPECT perfusion imaging. 
  • Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. 
  • Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. 
  • Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. 
  • Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. 
  • Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). 
  • Prediction of subsequent ischemic heart disease using serial resting electrocardiograms. 
  • Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. 
  • Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. 
  • Prediction of the infarct-related artery in acute myocardial infarction by a scoring system using summary ST-segment and T-wave changes. 
  • Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. 
  • Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. 
  • Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. 
  • Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. 
  • Predictors of Stroke, Myocardial Infarction or Death within 30 Days of Carotid Artery Stenting: Results from the International Carotid Stenting Study. 
  • Predictors of adherence to performance measures in patients with acute myocardial infarction. 
  • Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). 
  • Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. 
  • Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. 
  • Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. 
  • Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. 
  • Predictors of long-term clinical endpoints in patients with refractory angina. 
  • Predictors of morbidity and mortality with endovascular and open thoracic aneurysm repair. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. 
  • Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry. 
  • Predictors of outcome of reperfusion therapy. 
  • Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program). 
  • Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. 
  • Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. 
  • Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. 
  • Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. 
  • Preexcitation and myocardial infarction: conditions with confusing electrocardiographic manifestations. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. 
  • Prehospital system delay in ST-segment elevation myocardial infarction care: a novel linkage of emergency medicine services and in hospital registry data. 
  • Prehospital triage of acute myocardial infarction: wireless transmission of electrocardiograms to the on-call cardiologist via a handheld computer. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. 
  • Preoteomics, metabolomics and circulating endothelial progenitor cells in acute coronary syndromes. 
  • Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 
  • Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. 
  • Preservation of pre-excitation despite acute myocardial infarction complicated by complete heart block. 
  • Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. 
  • Prevalence and predictors of angina pectoris one month after myocardial infarction. 
  • Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India. 
  • Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus. 
  • Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America. 
  • Prevalence of apparent treatment-resistant hypertension among individuals with CKD. 
  • Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. 
  • Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. 
  • Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). 
  • Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. 
  • Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. 
  • Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. 
  • Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). 
  • Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. 
  • Primary PCI in ST-segment elevation myocardial infarction. 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Primary angioplasty vs thrombolysis in elderly patients. 
  • Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. 
  • Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). 
  • Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. 
  • Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. 
  • Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. 
  • Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. 
  • Procedural success and complications of large-scale screening colonoscopy. 
  • Processes of cumulative adversity: childhood disadvantage and increased risk of heart attack across the life course. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Progestin-only contraception and thromboembolism: A systematic review. 
  • Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock. The left main shock syndrome. 
  • Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. 
  • Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). 
  • Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. 
  • Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. 
  • Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. 
  • Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. 
  • Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. 
  • Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 
  • Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. 
  • Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. 
  • Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. 
  • Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. 
  • Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. 
  • Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. 
  • Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic models based on literature and individual patient data in logistic regression analysis. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. 
  • Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. 
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. 
  • Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. 
  • Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). 
  • Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 
  • Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. 
  • Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. 
  • Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). 
  • Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. 
  • Prognostic value of CT angiography in patients with inconclusive functional stress tests. 
  • Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. 
  • Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. 
  • Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. 
  • Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. 
  • Prognostic value of radionuclide exercise testing after myocardial infarction. 
  • Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. 
  • Prognostic value of thallium-201 single-photon emission computed tomography for patients with multivessel coronary artery disease after revascularization (the Emory Angioplasty versus Surgery Trial [EAST]). 
  • Prognostic value of the cadmium-zinc-telluride camera: A comparison with a conventional (Anger) camera. 
  • Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. 
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. 
  • Progress in the treatment of acute coronary syndromes: a 50-year perspective (1950-2000). 
  • Progressive left ventricular dysfunction and remodeling after myocardial infarction. 
  • Prolonged emergency department stays of non-ST-segment-elevation myocardial infarction patients are associated with worse adherence to the American College of Cardiology/American Heart Association guidelines for management and increased adverse events. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. 
  • Prospective demonstration of myocardial infarction by CT. 
  • Prospective evaluation of where reperfusion ventricular arrhythmia "bursts" fit into optimal reperfusion in STEMI. 
  • Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. 
  • Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR). 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). 
  • Provisional vs. complex stenting strategy for coronary bifurcation lesions: meta-analysis of randomized trials. 
  • Psychiatric morbidity during the early phase of coronary care for myocardial infarction: association with cardiac diagnosis and outcome. 
  • Psychobehavioral treatment in cardiac rehabilitation. 
  • Psychosocial characteristics after acute myocardial infarction: the ENRICHD pilot study. Enhancing Recovery in Coronary Heart Disease. 
  • Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. 
  • Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. 
  • Pulmonary function in acute myocardial infarction. 
  • Pursuing progress in acute coronary syndromes. 
  • Q wave myocardial infarction of anteroseptal zone: a new classification. 
  • Q: elevated serum creatine kinase (does/does not) equal myocardial infarction? 
  • QT prolongation and dispersion in myocardial ischemia and infarction. 
  • Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). 
  • Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. 
  • Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. 
  • Quality of life after late invasive therapy for occluded arteries. 
  • Quality of life after myocardial infarction: Canada versus the United States. 
  • Quality of medical care and excess mortality in older patients with mental disorders. 
  • Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. 
  • Quantification of ST-segment changes during coronary angioplasty in patients with left bundle branch block. 
  • Quantification of infarct size by 201Tl single-photon emission computed tomography during acute myocardial infarction in humans. Comparison with enzymatic estimates. 
  • Quantification of left ventricular infarcted mass on cardiac magnetic resonance imaging: comparison between planimetry and the semiquantitative visual scoring method. 
  • Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. 
  • Quantification of myocardial infarction: template model for serial creatine kinase analysis. 
  • Quantification of myocardial perfusion by MRI after coronary occlusion. 
  • Quantification of the contractile response to injury: assessment of the work-length relationship in the intact heart. 
  • Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. 
  • Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. 
  • Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. 
  • Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect. 
  • Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. 
  • Quantitative influence of serum creatine kinase isoenzyme MB estimated infarct size and other prognostic variables on one year mortality after acute myocardial infarction. 
  • Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction. 
  • ROC methodology within a monitoring framework. 
  • RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Race and Sex Differences in Post-Myocardial Infarction Angina Frequency and Risk of 1-Year Unplanned Rehospitalization. 
  • Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. 
  • Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. 
  • Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. 
  • Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of  
  • Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. 
  • Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. 
  • Racial variations in postoperative outcomes of carotid endarterectomy: evidence from the Veterans Affairs National Surgical Quality Improvement Program. 
  • Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). 
  • Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. 
  • Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: the RADIAL PUMP UP registry. 
  • Radionuclide emission computed tomography of the head with 99mCc and a scintillation camera. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. 
  • Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 
  • Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. 
  • Randomized trial of primary PCI with or without routine manual thrombectomy. 
  • Randomized trial of prostacyclin infusion in acute myocardial infarction. 
  • Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. 
  • Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. 
  • Rapid detection of myocardial infarction by subsecond, free-breathing delayed contrast-enhancement cardiovascular magnetic resonance. 
  • Rapid initial reduction of hyperenhanced myocardium after reperfused first myocardial infarction suggests recovery of the peri-infarction zone: one-year follow-up by MRI. 
  • Rapid screening for major depression in post-myocardial infarction patients: an investigation using Beck Depression Inventory II items. 
  • Rate of acute ST-elevation myocardial infarction in the United States from 1988 to 2004 (from the Nationwide Inpatient Sample). 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activation by emergency medical services or emergency physicians: results from the North Carolina Catheterization Laboratory Activation Registry. 
  • Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. 
  • Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. 
  • Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. 
  • Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: a randomized, prospective clinical investigation. 
  • Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. 
  • Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. 
  • Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. 
  • Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Re: Gender disparity in cardiac procedures and medication use for acute myocardial infarction. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Reassessing the clinical significance of ST-segment depression that occurs concomitantly with the ST-segment elevation during acute myocardial infarction with the use of continuous ST-segment analysis. 
  • Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy. 
  • Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. 
  • Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. 
  • Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. 
  • Recognition of postoperative acute myocardial infarction. Application of isoenzyme techniques. 
  • Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. 
  • Reconciling Systems for Acute Myocardial Infarction Definition and Coding Classification. 
  • Reconstruction of the standard 12-lead ECG from recordings using nonstandard activity-compatible proximal limb lead positions. 
  • Recovery from hospital-acquired anemia after acute myocardial infarction and effect on outcomes. 
  • Recurrent ischemia after thrombolysis for acute myocardial infarction. 
  • Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. 
  • Red blood cell indices and development of hospital-acquired anemia during acute myocardial infarction. 
  • Red cell distribution width and additive risk prediction for major bleeding in non-ST-segment elevation acute coronary syndrome. 
  • Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes. 
  • Redefining medical treatment in the management of unstable angina. 
  • Redefining the Gold Standard of Myocardial Infarction Using Troponin T. 
  • Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. 
  • Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. 
  • Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha1B-adrenergic receptors. 
  • Reducing cardiac events after acute coronary syndromes. 
  • Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease. 
  • Reevaluation of myoglobin for acute chest pain evaluation: would false-positive results on "first-draw" specimens lead to increased hospital admissions? 
  • Reference interval evaluation of high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam and the US: The North South East West Trial. 
  • Refinement and interobserver agreement for the electrocardiographic Sclarovsky-Birnbaum Ischemia Grading System. 
  • Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. 
  • Regarding "Anesthetic type and risk of myocardial infarction after carotid endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)". 
  • Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. 
  • Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines-Coronary Artery Disease (GWTG-CAD) registry. 
  • Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. 
  • Regional outcomes after admission for high-risk non-ST-segment elevation acute coronary syndromes. 
  • Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodology. 
  • Regional systems of care for ST-elevation myocardial infarction: do they save lives? 
  • Regional systems of care for out-of-hospital cardiac arrest: A policy statement from the American Heart Association. 
  • Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Regional versus general anesthesia for carotid endarterectomy: the American College of Surgeons National Surgical Quality Improvement Program perspective. 
  • Regionalization of ST-segment elevation myocardial infarction care: a task unfinished. 
  • Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. 
  • Rehabilitation of patients following myocardial infarction. 
  • Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. 
  • Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). 
  • Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. 
  • Relation between myocardial perfusion and left ventricular function following acute coronary occlusion: disproportionate effects of anterior vs. inferior ischemia. 
  • Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. 
  • Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. 
  • Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. 
  • Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. 
  • Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. 
  • Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. 
  • Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). 
  • Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. 
  • Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. 
  • Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. 
  • Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. 
  • Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). 
  • Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial. 
  • Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. 
  • Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. 
  • Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. 
  • Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Relationship between blood flow to ischemic regions and extent of myocardial infarction. Serial measurement of blood flow to ischemic regions in dogs. 
  • Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. 
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. 
  • Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. 
  • Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. 
  • Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. 
  • Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. 
  • Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. 
  • Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. 
  • Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. 
  • Relationship of T2-Weighted MRI Myocardial Hyperintensity and the Ischemic Area-At-Risk. 
  • Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. 
  • Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. 
  • Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. 
  • Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. 
  • Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. 
  • Relationship of the distance between non-PCI hospitals and primary PCI centers, mode of transport, and reperfusion time among ground and air interhospital transfers using NCDR's ACTION Registry-GWTG: a report from the American Heart Association Mission: Lifeline Program. 
  • Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. 
  • Relationships among ventricular arrhythmias, coronary artery disease, and angiographic and electrocardiographic indicators of myocardial fibrosis. 
  • Relationships between cardiac magnetic resonance imaging abnormalities in the inter-ventricular septum and Selvester QRS scoring criteria for anterior-septal myocardial infarction in patients with right ventricular volume overload. 
  • Relative increase in creatine kinase MB isoenzyme during reperfusion after myocardial infarction is method dependent. 
  • Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Removal of thrombus by catheter aspiration prior to stenting. 
  • Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. 
  • Renin and myocardial infarction in hypertension. 
  • Repair of postinfarction interventricular septal rupture. 
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. 
  • Reperfusion and revascularization strategies for coronary artery disease in women. 
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. 
  • Reperfusion for acute myocardial infarction: is the future in plastics? 
  • Reperfusion in waiting: what queue should we join? 
  • Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. 
  • Reperfusion paradox in ST-segment elevation myocardial infarction. 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. 
  • Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. 
  • Reperfusion strategies in acute coronary syndromes. 
  • Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. 
  • Reperfusion synergism: will it be both sustained and safe? 
  • Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: insights from the National Cardiovascular Data Registry (NCDR). 
  • Reperfusion ventricular arrhythmia 'bursts' in TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction: a more precise definition of reperfusion arrhythmias. 
  • Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. 
  • Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. 
  • Reply to Spiliopoulos et al. 
  • Reply: Effect of Pre-Procedural β-Blocker in Patients Undergoing Percutaneous Coronary Intervention. 
  • Reply: To PMID 22921873. 
  • Reply: To PMID 23265340. 
  • Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. 
  • Report of the Canadian Cardiovascular Society's consensus conference on the Management of the Postmyocardial Infarction Patient. 
  • Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. 
  • Representation of elderly persons and women in published randomized trials of acute coronary syndromes. 
  • Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. 
  • Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. 
  • Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. 
  • Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Respiratory motion and cardiac arrhythmia effects on diagnostic accuracy of myocardial delayed-enhanced MR imaging in canines. 
  • Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization". 
  • Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. 
  • Response to letter regarding article, "Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline Program". 
  • Response to letter regarding article, "The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry". 
  • Response to letter to the editor by Lin et al. 
  • Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. 
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Results of a reevaluation of cardiovascular outcomes in the RECORD trial. 
  • Results of high dose intravenous urokinase for acute myocardial infarction. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. 
  • Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. 
  • Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. 
  • Reverse redistribution on exercise thallium scintigraphy: relationship to coronary patency and ventricular function after myocardial infarction. 
  • Review: A single hs-cTnT with a cutpoint < limit of detection plus a nonischemic ECG can rule out acute MI. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Right ventricular infarction complicated by acute right-to-left shunting. 
  • Right ventricular infarction with shock but without significant left ventricular infarction: a new clinical syndrome. 
  • Risk Assessment and Characterization of 30-Day Perioperative Myocardial Infarction Following Spine Surgery: A Retrospective Analysis of 1346 Consecutive Adult Patients. 
  • Risk Factors For Stroke, Myocardial Infarction, or Death Following Carotid Endarterectomy: Results From the International Carotid Stenting Study. 
  • Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. 
  • Risk assessment for incident heart failure in individuals with atrial fibrillation. 
  • Risk assessment to predict arterial and venous events in patients undergoing percutaneous coronary intervention. 
  • Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. 
  • Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. 
  • Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). 
  • Risk factors for myocardial infarction in women and men. 
  • Risk factors for non-fatal myocardial infarction in young South Asian adults. 
  • Risk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarction. 
  • Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. 
  • Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. 
  • Risk of distal embolization and infarction with transluminal extraction atherectomy in saphenous vein grafts and native coronary arteries. NACI Investigators. New Approaches to Coronary Interventions. 
  • Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk profile of clinical trial participants--reply. 
  • Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. 
  • Risk stratification after myocardial infarction. 
  • Risk stratification after myocardial infarction. 
  • Risk stratification and therapeutic decision making in acute coronary syndromes. 
  • Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution. 
  • Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients. 
  • Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Role of cardiac evaluation before thoracic endovascular aortic repair. 
  • Role of coronary angiography in acute coronary artery syndromes. 
  • Role of nuclear imaging after coronary revascularization. 
  • Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. 
  • Routine Invasive Versus Selective Invasive Strategy in Elderly Patients Older Than 75 Years With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. 
  • Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. 
  • Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. 
  • Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 
  • Ruminating on OAT: is the case closed? 
  • SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. 
  • ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. 
  • ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. 
  • ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. 
  • ST-segment elevation myocardial infarction: recommendations on triage of patients to heart attack centers: is it time for a national policy for the treatment of ST-segment elevation myocardial infarction? 
  • ST-segment monitoring in patients with acute coronary syndromes. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • ST-segment recovery as an endpoint in acute myocardial infarction trials. Past, present, and future. 
  • ST-segment resolution and outcome in myocardial infarction. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • ST-segment-elevation myocardial infarction treatment and the seductive lure of observational analyses. 
  • STREAM characterisation correction. 
  • Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). 
  • Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare-linked National Cardiovascular Data Registry(®) CathPCI Registry(®) (2005-2009). 
  • Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data. 
  • Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. 
  • Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program. 
  • Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. 
  • Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. 
  • Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. 
  • Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Safety of gadoversetamide in patients with acute and chronic myocardial infarction. 
  • Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). 
  • Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. 
  • Sample size to test for interaction between a specific exposure and a second risk factor in a pair-matched case-control study. 
  • Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery? 
  • Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. 
  • Scintigraphic outlook of patients and regions with myocardial necrosis at myocardial perfusion scintigraphy. 
  • Screening for Hypertension and Lowering Blood Pressure for Prevention of Cardiovascular Disease Events. 
  • Screening for major depression in post-myocardial infarction patients: operating characteristics of the Beck Depression Inventory-II. 
  • Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. 
  • Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. 
  • Secondary prevention risk interventions via telemedicine and tailored patient education (SPRITE): a randomized trial to improve postmyocardial infarction management. 
  • Seeking the optimal aspirin dose in acute coronary syndromes. 
  • Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 
  • Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? 
  • Selection of patients for direct myocardial revascularization. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. 
  • Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. 
  • Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. 
  • Selvester QRS scoring in conduction abnormalitites: Caution recommended due to recent findings. 
  • Sensitive troponin I assay in patients with suspected acute coronary syndrome. 
  • Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. 
  • Sensitivity of a set of myocardial infarction screening criteria in patients with anatomically documented single and multiple infarcts. 
  • Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. 
  • Serial changes in the high-frequency ECG during the first year following acute myocardial infarction. 
  • Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Serial changes of soluble endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. 
  • Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. 
  • Serial evaluation of right ventricular dysfunction associated with acute inferior myocardial infarction. 
  • Serial prognostic capabilities of electrocardiographic indices of infarcted and hibernating myocardium in predicting short- and long-term outcome following coronary artery bypass surgery. 
  • Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. 
  • Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. 
  • Serum markers, myocardial marker content, and infarct size. 
  • Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction. 
  • Serum release of the creatine kinase tissue-specific isoforms MM3 and MB2 is simultaneous during myocardial reperfusion. 
  • Seven-year follow-up after dobutamine stress echocardiography: impact of gender on prognosis. 
  • Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease. 
  • Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. 
  • Sex differences in medical care after acute myocardial infarction: what can be done to address the problem? 
  • Sex differences in medical care and early death after acute myocardial infarction. 
  • Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. 
  • Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event. 
  • Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. 
  • Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. 
  • Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS. 
  • Sex-specific differences in the predictive value of cholesterol homeostasis markers and 10-year cardiovascular disease event rate in Framingham Offspring Study participants. 
  • Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. 
  • Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. 
  • Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. 
  • Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. 
  • Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. 
  • Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. 
  • Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery. 
  • Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? 
  • Should reperfusion strategies in myocardial infarction be modified for the very elderly? 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Should the intent of testing influence its interpretation? 
  • Significance of T-wave amplitude and dynamics at the time of reperfusion in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Significance of hemoptysis following thrombolytic therapy for acute myocardial infarction. 
  • Significance of high degree atrioventricular block in acute posterior myocardial infarction. The importance of clinical setting and mechanism of block. 
  • Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. 
  • Simple principles of clinical trials remain powerful. 
  • Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. 
  • Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events. 
  • Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. 
  • Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. 
  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. 
  • Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. 
  • Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. 
  • Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram. 
  • Skeletal muscle deoxygenation abnormalities in early post-myocardial infarction. 
  • Slow Gait Speed and Risk of Mortality or Hospital Readmission After Myocardial Infarction in the Translational Research Investigating Underlying Disparities in Recovery from Acute Myocardial Infarction: Patients' Health Status Registry. 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. 
  • Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study. 
  • Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. 
  • Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction. 
  • Socioeconomic disparities in outcomes after acute myocardial infarction. 
  • Socioeconomic position, John Henryism, and incidence of acute myocardial infarction in Finnish men. 
  • Socioeconomic status and outcome following acute myocardial infarction in elderly patients. 
  • Sodium nuclear magnetic resonance imaging of myocardial tissue of dogs after coronary artery occlusion and reperfusion. 
  • Soluble PECAM-1, but not P-selectin, nor osteonectin identify acute myocardial infarction in patients presenting with chest pain. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). 
  • Special Considerations in the Management of Diabetes in Women. 
  • Species variability in angiotensin receptor expression by cultured cardiac fibroblasts and the infarcted heart. 
  • Specificity of electrocardiographic myocardial infarction screening criteria in patients with nonischemic cardiomyopathies. 
  • Spirituality, religion, and clinical outcomes in patients recovering from an acute myocardial infarction. 
  • Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. 
  • Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 
  • State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. 
  • Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart association. 
  • Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). 
  • Statistical analysis of signals from an intracavitary probe in a diseased heart. 
  • Stem cells for the ischaemic heart. 
  • Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. 
  • Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Stress cardiac magnetic resonance imaging provides effective cardiac risk reclassification in patients with known or suspected stable coronary artery disease. 
  • Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. 
  • Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. 
  • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Success stories: how hospitals are improving care. 
  • Sudden cardiac death in young children with neurofibromatosis type 1. 
  • Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. 
  • Sudden death in patients with myocardial infarction. 
  • Summary of evidence regarding hospital strategies to reduce door-to-balloon times for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Supplement on acute coronary syndromes: introduction. 
  • Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. 
  • Surgical correction of ventricular septal defect following acute myocardial infarction. 
  • Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. 
  • Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. 
  • Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool. 
  • Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. 
  • Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. 
  • Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. 
  • System dynamics modeling in the evaluation of delays of care in ST-segment elevation myocardial infarction patients within a tiered health system. 
  • Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease. 
  • Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. 
  • Systolic contraction within aneurysmal rabbit myocardium following transplantation of autologous skeletal myoblasts. 
  • Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group. 
  • T2-weighted imaging to assess post-infarct myocardium at risk. 
  • TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. 
  • TIMI IIB follow-up. Lessons for clinicians and investigators. 
  • TIMI frame count: a quantitative method of assessing coronary artery flow. 
  • TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. 
  • Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit. 
  • Takotsubo cardiomyopathy: an unusual syndrome mimicking an ST-elevation myocardial infarction. 
  • Tamoxifen reduces plasma homocysteine levels in healthy women. 
  • Tardy Pardee: moving medical effectiveness to the forefront. 
  • Targeted versus standard feedback: results from a randomized quality improvement trial. 
  • Targeting lifestyle change in patients with depression. 
  • Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up. 
  • Technology insight: MRI of the myocardium. 
  • Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. 
  • Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. 
  • Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction. 
  • Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. 
  • Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empiric fit with the log-normal function. 
  • Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. 
  • Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. 
  • Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. 
  • Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. 
  • Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. 
  • Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. 
  • Temporal trends in medical therapies for ST- and non-ST elevation myocardial infarction: (from the Atherosclerosis Risk in Communities [ARIC] Surveillance Study). 
  • Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. 
  • Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States. 
  • Temporary balloon occlusion of the inferior vena cava for immediate reversal of acute pulmonary edema. 
  • Ten years of benefit from a one-hour intervention. 
  • Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. 
  • Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). 
  • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. 
  • The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. 
  • The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. 
  • The Association of Kidney Function and Albuminuria With the Risk and Outcomes of Syncope: A Population-Based Cohort Study. 
  • The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. 
  • The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. 
  • The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. 
  • The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. 
  • The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. 
  • The Choice Is Reperfusion Therapy: But Which One? 
  • The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea. 
  • The Diagnostic Utility of Cardiovascular Magnetic Resonance (CMR) in Patients With Chest Pain, Elevated Cardiac Enzymes, and Non-Obstructed Coronary Arteries. 
  • The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. 
  • The Fuzzy Math of Anticoagulation and Access Site: When 1 + 1 Does Not Always Equal 2. 
  • The GUSTO trial and the open artery theory. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The Many Faces of Type 2 Myocardial Infarction. 
  • The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. 
  • The New York State Primary Angioplasty Registry and procedural volume. 
  • The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. 
  • The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)--evaluating the impact of myocardial infarction on patient outcomes. 
  • The Role of Mean Blood Pressure at Admission in Patients Undergoing Primary Percutaneous Coronary Intervention. 
  • The STAFF studies of the first 5 minutes of percutaneous coronary angioplasty balloon occlusion in man. 
  • The STICH trial: evidence-based conclusions. 
  • The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system. 
  • The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. 
  • The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. 
  • The aorta wall of patients presenting to the emergency department with acute myocardial infarction by cardiac magnetic resonance. 
  • The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. 
  • The association between institutional primary angioplasty procedure volume and outcome in elderly Americans. 
  • The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients. 
  • The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. 
  • The association of in-hospital guideline adherence and longitudinal postdischarge mortality in older patients with non-ST-segment elevation myocardial infarction. 
  • The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. 
  • The association of myocardial infarction process of care measures and in-hospital mortality: a report from the NCDR®. 
  • The association of pre- and posthospital medication adherence in myocardial infarction patients. 
  • The benefits of moving quality to a national level. 
  • The bispectral index in the diagnosis of perioperative stroke: a case report and discussion. 
  • The cart and the horse: the advancing technology of carotid artery stenting. 
  • The chest-pain unit--ready for prime time? 
  • The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective. 
  • The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. 
  • The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. 
  • The complexity of studying coronary heart disease in women. 
  • The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity. 
  • The concordance of intraoperative left ventricular wall-motion abnormalities and electrocardiographic S-T segment changes: association with outcome after coronary revascularization. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. 
  • The conundrum of reducing ischemic and bleeding events after PCI. 
  • The correlation between presenting ST-segment depression and the final size of acute myocardial infarcts in patients with acute coronary syndromes. 
  • The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. 
  • The course of acute myocardial infarction. Feasibility of early discharge of the uncomplicated patient. 
  • The cumulative effect of unemployment on risks for acute myocardial infarction. 
  • The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. 
  • The devil is in the details: the need for integrated cardiovascular data for performance measures and feedback. 
  • The diagnosis of acute myocardial infarction. 
  • The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). 
  • The diagnostic utility of cardiovascular magnetic resonance in patients with chest pain, elevated cardiac enzymes and non-obstructed coronary arteries. 
  • The direct incorporation of perfusion defect information to define ischemia and infarction in a finite element model of the left ventricle. 
  • The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. 
  • The dynamics of dimensions of age-related disability 1982 to 1994 in the U.S. elderly population. 
  • The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. 
  • The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial. 
  • The effect of age on functional and mortality outcomes after acute myocardial infarction. 
  • The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. 
  • The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study. 
  • The effect of lithium carbonate administration in patients with advanced small cell bronchogenic carcinoma receiving combination chemotherapy and radiotherapy. 
  • The effect of managed care penetration on the treatment of AMI in the fee-for-service Medicare population. 
  • The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy. 
  • The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • The effects of New York's bypass surgery provider profiling on access to care and patient outcomes in the elderly. 
  • The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. 
  • The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • The emerging role of myoglobin for risk stratification. 
  • The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations. 
  • The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. 
  • The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database. 
  • The extracellular matrix protein agrin promotes heart regeneration in mice. 
  • The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. 
  • The fate of inorganic phosphate and pH in regional myocardial ischemia and infarction: a noninvasive 31P NMR study. 
  • The feasibility of myocardial infarct visualization using atrial kick induced strain (AKIS) contrast. 
  • The first ISCE Board of "Trustees" overview panel session: ischemia monitoring, state of the art. International Society of Computerized Electrocardiology. 
  • The forgotten chamber: the importance of the right ventricle. 
  • The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients? 
  • The healthy diver: A cross-sectional survey to evaluate the health status of recreational scuba diver members of Divers Alert Network (DAN). 
  • The hemodynamic simulation of mitral regurgitation in ventricular septal defect after myocardial infarction. 
  • The impact of Centers for Medicare and Medicaid Services high-risk criteria on outcome after carotid endarterectomy and carotid artery stenting in the SVS Vascular Registry. 
  • The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment times. 
  • The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. 
  • The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. 
  • The impact of coronary artery disease on carotid endarterectomy. 
  • The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE Initiative. 
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. 
  • The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. 
  • The impact of late career job loss on myocardial infarction and stroke: a 10 year follow up using the health and retirement survey. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The impact of postrandomization crossover of therapy in acute coronary syndromes care. 
  • The impact of processes of care on myocardial infarct size in patients with ST-segment elevation myocardial infarction: observations from the CRISP-AMI trial. 
  • The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. 
  • The importance of consistent, high-quality acute myocardial infarction and heart failure care results from the American Heart Association's Get with the Guidelines Program. 
  • The influence of age on health status outcomes after acute myocardial infarction. 
  • The influence of editing on the performance of a computer program for serial comparison of electrocardiograms. 
  • The influence of race on health status outcomes one year after an acute coronary syndrome. 
  • The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. 
  • The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. 
  • The initial electrocardiographic pattern in acute myocardial infarction: correlation with infarct size. 
  • The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. 
  • The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort. 
  • The irony of biased editors who write editorials. GUSTO Investigators. 
  • The late presenting STEMI: How ECG scores can be used to estimate event time. 
  • The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry. 
  • The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? 
  • The management of acute coronary insufficiency. 
  • The myocardial area at risk. 
  • The natural history of single-vessel chronic coronary occlusion: a 25-year experience. 
  • The need for regional integrated care for ST-segment elevation myocardial infarction. 
  • The need for wider utilization of thrombolytic therapy. 
  • The noninvasive localization of ventricular pacing sites by radionuclide phase imaging. 
  • The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. 
  • The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. 
  • The platelet-related effects of tenecteplase versus alteplase versus reteplase. 
  • The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: a preliminary report of a new device for the noninvasive detection of successful reperfusion or silent coronary reocclusion. 
  • The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. 
  • The predictive value of an ECG-estimated Acute Ischemia Index for prognosis of myocardial salvage and infarct healing 3months following inferior ST-elevated myocardial infarction. 
  • The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). 
  • The problem of decompensated heart failure: nomenclature, classification, and risk stratification. 
  • The prognosis for patients with new-onset angina who have undergone cardiac catheterization. 
  • The prognostic implications of negative T waves in the leads with ST segment elevation on admission in acute myocardial infarction. 
  • The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. 
  • The prognostic value of dobutamine stress echocardiography in patients with abdominal aortic aneurysm and concomitant coronary artery disease. 
  • The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen. 
  • The rational clinical examination. Is this patient having a myocardial infarction? 
  • The rationale for thrombolytic therapy. 
  • The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. 
  • The relationship between cholesterol level and myocardial infarction or mortality risk in patients with coronary artery disease. A report from the Coronary Artery Surgery Study (CASS) registry. 
  • The relationship between enzymatic and histologic estimates of the extent of myocardial infarction in conscious dogs with permanent coronary occlusion. 
  • The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 
  • The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. 
  • The relationship between serial postinfarction T wave changes and infarct size and ventricular function as determined by cardiac magnetic resonance imaging. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The reply. 
  • The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. 
  • The role of angioplasty after failed thrombolysis for acute myocardial infarction. 
  • The role of angioplasty after successful thrombolysis for acute myocardial infarction. 
  • The role of aspirin in cardiovascular diseases--forgotten benefits? 
  • The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non-ST-elevation myocardial infarction patients: design and rationale of the CARdiovascular Magnetic rEsoNance imaging and computed Tomography Angiography (CARMENTA) trial. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • The role of diabetes mellitus in the composition of coronary thrombi in patients presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • The role of fibrinolytics in the prehospital treatment of ST-elevation myocardial infarction (STEMI). 
  • The role of platelet receptors and adhesion molecules in coronary artery disease. 
  • The role of psychiatric and behavioral factors in the practice of medicine. 
  • The role of reperfusion therapy in paced patients with acute myocardial infarction. 
  • The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. 
  • The search for myocardial protection: is there still hope? 
  • The significance of coronary calcification detected by fluoroscopy. A report of 360 patients. 
  • The spectrum of unstable angina: prognostic role of serum creatine kinase determination. 
  • The standard 11-lead ECG. Neglect of lead aVR in the classical limb lead display. 
  • The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. 
  • The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. 
  • The triggering of myocardial infarction by fine particles is enhanced when particles are enriched in secondary species. 
  • The use of 111In-labelled autologous neutrophils in imaging myocardial infarction. 
  • The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. 
  • The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. 
  • The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. 
  • The use of intraaortic balloon counterpulsation in acute myocardial infarction and high risk coronary angioplasty. 
  • The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. 
  • The utility of C4d, C9, and troponin T immunohistochemistry in acute myocardial infarction. 
  • The utility of troponin measurement to detect myocardial infarction: review of the current findings. 
  • The utility of upper endoscopy in patients with concomitant upper gastrointestinal bleeding and acute myocardial infarction. 
  • The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups. 
  • The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. 
  • Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Third World profile of racial differences in thrombolytic effects of streptokinase. 
  • Third universal definition of myocardial infarction. 
  • Third universal definition of myocardial infarction. 
  • Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. 
  • Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data). 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. 
  • Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Thrombolysis and angioplasty in acute myocardial infarction. 
  • Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. 
  • Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. 
  • Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Thrombolytic Therapy for Acute Myocardial Infarction : A Review. 
  • Thrombolytic therapy for acute myocardial infarction: GUSTO criticized. 
  • Thrombolytic therapy for elderly patients. 
  • Thrombolytic therapy for myocardial infarction. 
  • Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. 
  • Thrombolytic therapy: time to treatment. 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. 
  • Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 
  • Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. 
  • Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. 
  • Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. 
  • Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. 
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. 
  • Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Time to presentation with acute myocardial infarction in the elderly: associations with race, sex, and socioeconomic characteristics. 
  • Time to reperfusion in acute myocardial infarction. It is time to reduce it! 
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. 
  • Time to treatment as a quality metric for acute STEMI care. 
  • Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. 
  • Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. 
  • Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. 
  • Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. 
  • Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction. 
  • Timing of Complications Occurring Within 30 Days After Adult Spinal Deformity Surgery. 
  • Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). 
  • Timing of magnesium therapy affects experimental infarct size. 
  • Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. 
  • Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 
  • Tissue plasminogen activator: why the backlash? 
  • Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. 
  • Tl-201 single-photon emission computed tomography (SPECT) 
  • To the editor. 
  • To transfer or not to transfer: acute myocardial infarction reperfusion. 
  • Total shoulder arthroplasty in patients with HIV infection: complications, comorbidities, and trends. 
  • Toward a therapeutic window for antiplatelet therapy in the elderly. 
  • Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe. 
  • Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Transient QRS changes simulating acute myocardial infarction. 
  • Transient electrocardiographic changes of elective coronary angioplasty compared with evolutionary changes of subsequent acute myocardial infarction observed with continuous three-lead monitoring. 
  • Transient reversal of bifascicular block during acute myocardial infarction with reperfusion therapy: a word of caution. 
  • Transition of care for acute stroke and myocardial infarction patients: from hospitalization to rehabilitation, recovery, and secondary prevention. 
  • Transitional care after hospitalization for acute stroke or myocardial infarction: a systematic review. 
  • Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction. 
  • Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. 
  • Transluminal intracoronary reperfusion catheter: a device to maintain coronary perfusion between failed coronary angioplasty and emergency coronary bypass surgery. 
  • Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. 
  • Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. 
  • Transport time and care processes for patients transferred with ST-segment-elevation myocardial infarction: the reperfusion in acute myocardial infarction in Carolina emergency rooms experience. 
  • Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. 
  • Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? 
  • Treating myocardial infarction in the post-GUSTO era. A US perspective. 
  • Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). 
  • Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? 
  • Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology's NCDR(®). 
  • Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. 
  • Treatment of acute myocardial infarction. 
  • Treatment of hyperlipidemia by specialists versus generalists as secondary prevention of coronary artery disease. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. 
  • Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. 
  • Treatment pathways and quality improvement for patients with acute myocardial infarction at a tertiary care center. 
  • Treatment strategies for microvascular dysfunction following acute myocardial infarction. 
  • Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid-Eligible Adults With Myocardial Infarction. 
  • Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. 
  • Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. 
  • Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). 
  • Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. 
  • Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. 
  • Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. 
  • Trends in emergency coronary artery bypass grafting after percutaneous coronary intervention, 1994-2003. 
  • Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. 
  • Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. 
  • Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in referral to cardiac rehabilitation after myocardial infarction: data from the National Cardiovascular Data Registry 2007 to 2012. 
  • Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in the surgical treatment of ischemic mitral regurgitation: effects of mitral valve repair on hospital mortality. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Trials in myocardial infarction. 
  • Triggering of transmural infarctions, but not nontransmural infarctions, by ambient fine particles. 
  • Triggers of acute coronary syndromes. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Troponin Elevation After Colorectal Surgery: Significance and Management. 
  • Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. 
  • Troponin and other cardiac markers: role in management of acute coronary syndromes. 
  • Troponin criteria for myocardial infarction after percutaneous coronary intervention. 
  • Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. 
  • Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. 
  • Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. 
  • Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. 
  • Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. 
  • Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. 
  • Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. 
  • Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment. 
  • Type 2 Myocardial Infarction　- An Evolving Entity. 
  • Type 2 myocardial infarction due to supply-demand mismatch. 
  • Type A behavior and survival: a follow-up study of 1,467 patients with coronary artery disease. 
  • Type A behavior, nonverbal expressive style, and health. 
  • Ultrasound diagnosis of pseudoaneurysm and contiguous ventricular septal defect complicating inferior myocardial infarction. 
  • Uncoupling associations of risk alleles with endophenotypes and phenotypes: insights from the ApoB locus and heart-related traits. 
  • Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. 
  • Understanding and Targeting Inflammation in Acute Myocardial Infarction: An Elusive Goal. 
  • Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors. 
  • Underuse of aspirin in a referral population with documented coronary artery disease. 
  • Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. 
  • United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease). 
  • Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. 
  • Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. 
  • Unstable angina pectoris: National Cooperative Study Group to Compare Medical and Surgical Therapy. IV. Results in patients with left descending coronary artery disease. 
  • Unstable angina pectoris: National Cooperative Study Group to Compare Surgical and Medical Therapy. 
  • Unstable angina pectoris: national cooperative study group to compare surgical and medical therapy. III. Results in patients with S-T segment elevation during pain. 
  • Unstable angina--report from a Canadian expert roundtable. 
  • Unstable infarct artery. Quantification across angiographic subgroups using continuous digital 12-lead ST-segment recovery analysis. 
  • Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 
  • Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. 
  • Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. 
  • Use of Implantable Cardioverter-Defibrillators Among Medicare Patients--Reply. 
  • Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 
  • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. 
  • Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). 
  • Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. 
  • Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. 
  • Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction. 
  • Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. 
  • Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation: insights from CRUSADE. 
  • Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarcts. 
  • Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. 
  • Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. 
  • Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. 
  • Use of prehospital 12-lead electrocardiography and treatment times among ST-elevation myocardial infarction patients with atypical symptoms. 
  • Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. 
  • Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). 
  • Use of serum markers to measure acute myocardial infarct size: lessons of a nonlinear dynamical model. 
  • Use of stress testing and diagnostic catheterization after coronary stenting: association of site-level patterns with patient characteristics and outcomes in 247,052 Medicare beneficiaries. 
  • Use of the 12-lead ECG to detect myocardial reperfusion and salvage during acute myocardial infarction. 
  • Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. 
  • Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. 
  • Use of the peak troponin value to differentiate myocardial infarction from reversible neurogenic left ventricular dysfunction associated with aneurysmal subarachnoid hemorrhage. 
  • Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. 
  • Use of valsartan in post-myocardial infarction and heart failure patients. 
  • Usefulness of Intra-aortic Balloon Pump Counterpulsation. 
  • Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. The TAMI Study Group. 
  • Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). 
  • Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease. 
  • Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. 
  • Usefulness of quantitative baseline ST-segment elevation for predicting outcomes after primary coronary angioplasty or fibrinolysis (results from the DANAMI-2 trial). 
  • Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). 
  • Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. 
  • Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 
  • Utility of observation units for young emergency department chest pain patients. 
  • Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. 
  • Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. 
  • Validation of advanced ECG diagnostic software for the detection of prior myocardial infarction by using nuclear cardiac imaging. 
  • Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? 
  • Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. 
  • Validity of reported genetic risk factors for acute coronary syndrome. 
  • Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. 
  • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Valsartan, captopril, or both in myocardial infarction. 
  • Value of radionuclide angiography for predicting specific cardiac events after acute myocardial infarction. 
  • Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. 
  • Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. 
  • Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. 
  • Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. 
  • Variations in coronary procedure utilization depending on body mass index. 
  • Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. 
  • Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. 
  • Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. 
  • Vascular factors predict rate of progression in Alzheimer disease. 
  • Vasodilator therapy in acute myocardial infarction. A comparison of sodium nitroprusside and nitroglycerin. 
  • Vectorcardiographic assessment of anterior and apical myocardial infarction. 
  • Vectorcardiographic criteria for the diagnosis of anterior myocardial infarction. 
  • Vectorcardiographic criteria for the diagnosis of inferior myocardial infarction. 
  • Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. 
  • Ventricular arrhythmias during reperfusion. 
  • Ventricular ectopy: impact of self-reported stress after myocardial infarction. 
  • Very early acute myocardial infarct treated with streptokinase and balloon angioplasty. 
  • Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MB(mass) 
  • Viability assessment by delayed enhancement cardiovascular magnetic resonance: will low-dose dobutamine dull the shine? 
  • Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. 
  • Visit-to-Visit Blood Pressure Variability and Mortality and Cardiovascular Outcomes Among Older Adults: The Health, Aging, and Body Composition Study. 
  • Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. 
  • Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. 
  • Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. 
  • Volume-outcome relationship in acute myocardial infarction: the balloon and the needle. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. 
  • Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. 
  • Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. 
  • Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. 
  • Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. 
  • We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization. 
  • Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. 
  • Weight change after myocardial infarction--the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) experience. 
  • What aspects of hospital culture influence quality? 
  • What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? 
  • What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? 
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? 
  • What's in a Name? The New ICD-10 (10th Revision of the International Statistical Classification of Diseases and Related Health Problems) Codes and Type 2 Myocardial Infarction. 
  • When is angina good? Preconditioning in acute myocardial infarction. 
  • When to implant an ICD following a myocardial infarction? 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
  • Which is the true channel? 
  • White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). 
  • Who are the MADIT patients? Multicenter Automatic Defibrillator Implantation Trial. 
  • Who should have a routine early invasive approach after fibrinolytic therapy? 
  • Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. 
  • Whose heart will get broken? Troponin testing and future heart failure. 
  • Why Is Infarct Expansion Such an Elusive Therapeutic Target? 
  • Why are (only) some infarcted hearts arrhythmogenic? 
  • Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: case report and review of the literature. 
  • Willingness of Patients to Use Computers for Health Communication and Monitoring Following Myocardial Infarction. 
  • Wine drinking is associated with increased heart rate variability in women with coronary heart disease. 
  • Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues. 
  • Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? 
  • Zofenopril after anterior myocardial infarction. 
  • [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. 
  • [Canadian Consensus Conference on Coronary Thrombolysis--current aspects]. 
  • [Electrocardiography and serum CK-MB determination in myocardial infarction and reperfusion in patients treated with intravenous streptokinase or placebo] 
  • [Fourth universal definition of myocardial infarction (2018)]. 
  • [Influence of the anatomical pattern of the coronary arteries on myocardial infarction]. 
  • [Prayers for patients with internal and cardiological diseases--an applicable therapeutic method?]. 
  • [Predictive value of the GRACE discharge score on the long-term out-of-hospital coronary thrombotic events after implantation of drug-eluting stents]. 
  • [Serum creatine kinase isoenzyme MB and myoglobin in patients with acute myocardial infarction and coronary reperfusion]. 
  • [Serum myoglobin as a non-invasive marker of coronary reperfusion after intravenous thrombolytic therapy in patients with acute myocardial infarction]. 
  • β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. 
  • β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Radiology
  • Bettger, Janet Prvu, Associate Professor of Orthopaedic Surgery, School of Nursing
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Bursac, Nenad, Professor of Biomedical Engineering, Biomedical Engineering
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Johnson, G. Allan, Charles E. Putman University Professor of Radiology, Physics
  • Limkakeng Jr., Alexander Tan, Associate Professor of Surgery, Surgery, Emergency Medicine
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Shaw, Ryan, Elizabeth C. Clipp Term Chair of Nursing, Duke Innovation & Entrepreneurship
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Williams Jr., Judson Blount, Assistant Consulting Professor in the Department of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine